fulltext01
Transcription
fulltext01
Linköping University Medical Dissertations No.996 Pro- and Anti-inflammatory Regulation of β2 Integrin Signalling in Human Neutrophils Veronika Patcha Brodin Division of Cell Biology Department of Biomedicine and Surgery Faculty of Health Sciences, Linköping University SE-581 85 Linköping SWEDEN Linköping 2007 Cover image: Fluorescence image of differentiated HL60 cells phagocytosing yeast. Shown in the image; F-actin depicted in red, and yeast in grey. © Veronika Brodin All rights reserved ISSN: 0345-0082 ISBN: 978-91-85715-22-0 The published articles are reprinted with the permission from the publishers Printed by LiU-Tryck, Linköping, Sweden 2007 To Greger, Ella, and Alexander …and all the curious people out there ABSTRACT The body is under constant attack from pathogens trying to slip by our immune defence. If the barrier is breached, invading pathogens enter the tissues and cause inflammation. During this process neutrophils, constituting the first line of defence, leave the bloodstream and seek out and kill the invading pathogens. The mechanisms leading to activation of receptors on neutrophils must be closely orchestrated. Pro- and anti-inflammatory substances can influence the outcome of the inflammation process by affecting the involved players. If not well balanced, inflammatory diseases, such as atherosclerosis and rheumatoid arthritis, can be the outcome. The aim of this thesis was to elucidate the effect of pro- (fMLP, Leukotriene B4, and Interleukin-8) and anti- (lipoxins, aspirin and statins) inflammatory substances on the β2 integrins, mediating adhesion of neutrophils both under “normal” conditions and during coronary artery disease. More specifically, the effect of these substances on the β2 integrins were studied in regard to: i) the activity (i.e. affinity and avidity) of β2 integrins, ii) the signalling capacity of β2 integrins (i.e. detected as release of arachidonic acid, and the production of reactive oxygen species, and iii) the signal transduction mediated by the β2 integrins (i.e. phosphorylation of Pyk2). The pro-inflammatory substances belong to the family of chemoattractants that induces transmigration and chemotaxis. A hierarchy exists between the different family members; the end-target chemoattractants (e.g. fMLP) being more potent than intermediary chemoattractants (e.g. IL-8 and LTB4). It was found that intermediary chemoattractants B regulate β2 integrins by mainly affecting the avidity of β2 integrins. End-target chemoattractants on the other hand, affected the β2 integrins by increasing the avidity and the affinity, as well as their signalling capacity. The anti-inflammatory substances used in this study were the exogenous aspirin and statins, and the endogenous lipoxins. In the presence of aspirin, stable analogues of lipoxin (i.e. epilipoxins) are formed in a trans-cellular process. Lipoxin inhibited the signalling capacity of β2 2 integrins mediated by intermediary chemoattractants, as well as the signal transduction induced by end-target chemoattractants. Moreover, the signalling capacity of β2 integrins in neutrophils from patients suffering from coronary artery disease (CAD) was impaired. Arachidonic acid, the precursor for both pro- and anti-inflammatory eicosanoid, induced an increase in the β2 integrin activity (both affinity and avidity), but had no effect on the signal transduction. In conclusion, different “roles” were observed for end-target and intermediary chemoattractants in the regulation of β2 integrins. The inhibitory effects of the antiinflammatory lipoxins support earlier studies suggesting that these agents function as “stop signals” in inflammation. This is also confirmed by our findings in CAD patients, who have elevated levels of epi-lipoxins due to aspirin treatment. Moreover, Pyk2 was identified as a possible target for the inhibitory effect of anti-inflammatory drugs. 3 PREFACE This thesis is based on the following papers, referred to by their Roman numerals (I-V): I) Patcha V, Wigren J, Winberg ME, Rasmusson B, Li J, and Särndahl E: Differential inside-out activation of β2-integrins by leukotriene B4 and fMLP in human neutrophils. Exp. Cell Res. 300: 308-318, 2004. II) Patcha Brodin V and Särndahl E: Lipoxin A4 inhibits the fMet-Leu-Pheinduced, but not β2 integrin-induced activation of the non-receptor tyrosine kinase Pyk2 in human leukemia cells (HL-60). Manuscript 2007, submitted III) Patcha Brodin V and Särndahl E: Inside-out regulated, β2 integrin-induced release of arachidonic acid in Human Leukemia 60 cells. Manuscript 2007, submitted IV) Lerm M, Patcha Brodin V, Ruishalme I, Stendahl O, and Särndahl E: Inactivation of Cdc42 is necessary for depolymerization of phagosomal F-actin and subsequent phagosomal maturation. Accepted for publication in J. Immunol. V) Särndahl E, Bergström I, Patcha Brodin V, Nijm J, Lundqvist-Setterud H, and Jonasson L: Neutrophil activation status in stable coronary artery disease. Manuscript 2007, submitted 4 5 CONTENTS ABSTRACT........................................................................................................................................................... 2 PREFACE.............................................................................................................................................................. 4 CONTENTS........................................................................................................................................................... 6 ABBREVIATIONS ............................................................................................................................................... 8 INTRODUCTION............................................................................................................................................... 12 ADHESION ........................................................................................................................................................ 12 THE ACTIN CYTOSKELETON ............................................................................................................................. 13 INTEGRINS ........................................................................................................................................................ 14 Integrin activation: affinity, avidity, and valency........................................................................................ 16 β2 integrin ligation ..................................................................................................................................... 18 INTEGRINS, PARTNERS IN SICKNESS AND IN HEALTH ...................................................................................... 20 INTEGRINS, MATRIX ADHESIONS AND ASSOCIATED PROTEINS ........................................................................ 21 Cytoskeletal proteins associated with adhesion complexes......................................................................... 21 Proteins involved in mediating signal transduction induced by integrins................................................... 23 CELL MOTILITY ................................................................................................................................................. 25 REGULATION OF ADHESION SIGNALLING BY LIPID METABOLITES ................................................................... 26 Phosholipase A2 .......................................................................................................................................... 26 Arachidonic acid and pro-inflammatory eicosanoids.................................................................................. 27 Anti-inflammatory lipoxins .......................................................................................................................... 28 PHAGOCYTOSIS................................................................................................................................................ 29 The phagocytic process ............................................................................................................................... 29 Degranulation.............................................................................................................................................. 30 AIMS OF THE INVESTIGATION................................................................................................................... 31 METHODS .......................................................................................................................................................... 33 NEUTROPHILS .................................................................................................................................................. 33 [3H]ARACHIDONIC ACID-LABELLING AND RELEASE ........................................................................................ 34 CELL STIMULATION .......................................................................................................................................... 34 Activation by chemotactic factors................................................................................................................ 34 Integrin ligation........................................................................................................................................... 34 FLOW CYTOMETRY ........................................................................................................................................... 35 Expression of β2-integrins.......................................................................................................................... 37 β2 integrin affinity ...................................................................................................................................... 37 Binding of soluble ICAM-1.......................................................................................................................... 38 FLUORESCENCE MICROSCOPY ........................................................................................................................ 38 SINGLE PARTICLE TRACKING .......................................................................................................................... 38 CONFOCAL SCANNING LIGHT MICROSCOPY................................................................................................... 39 IMAGE ANALYSIS .............................................................................................................................................. 40 Clustering of integrins ................................................................................................................................. 40 Granule distribution .................................................................................................................................... 40 INTRODUCTION OF RECOMBINANT PROTEINS INTO HUMAN NEUTROPHILS ..................................................... 40 HIV TAT PROTEINS .......................................................................................................................................... 41 TAT transduction ......................................................................................................................................... 41 IMMUNOPRECIPITATION AND WESTERN BLOT ................................................................................................. 42 PHAGOCYTOSIS AND PRODUCTION OF REACTIVE OXYGEN SPECIES .............................................................. 42 STATISTICAL ANALYSIS.................................................................................................................................... 42 RESULTS ............................................................................................................................................................ 44 THE EFFECT OF PRO- AND ANTI-INFLAMMATORY CHEMOATTRACTANTS ON THE ACTIVATION STATE OF THE β2 INTEGRINS .................................................................................................................................................. 44 6 The activation state of β2 integrins on neutrophils from healthy donors, mediated by pro-inflammatory chemoattractants ......................................................................................................................................... 44 The effect of anti-inflammatory substances on the activation state of β2 integrins.................................... 45 The activation state of β2 integrins on neutrophils from patients with stable CAD ................................... 46 THE EFFECT OF PRO- AND ANTI- INFLAMMATORY SUBSTANCES ON THE SIGNALLING CAPACITY OF β2 INTEGRINS ........................................................................................................................................................ 47 Signalling capacity, as measured by the release of arachidonic acid ......................................................... 47 The signalling capacity of β2 integrins, measured by production of reactive oxygen species ................... 50 THE EFFECT OF PRO- AND ANTI-INFLAMMATORY SUBSTANCES ON THE SIGNAL TRANSDUCTION MEDIATED BY β2 INTEGRINS.................................................................................... 51 ADDITIONAL METHODS TO STUDY PROTEINS IMPORTANT FOR THE REGULATION OF β2 INTEGRINS ............. 54 TAT-protein transduction ............................................................................................................................ 55 Transduction of HL60 cells with TAT-Pyk2 ................................................................................................ 57 SUMMARY ......................................................................................................................................................... 58 CONCLUDING REMARKS AND FUTURE PERSPECTIVES.................................................................... 59 ACKNOWLEDGEMENTS................................................................................................................................ 60 REFERENCES.................................................................................................................................................... 65 7 ABBREVIATIONS AA ATL BSA CAD COX CR3 CRP C3b C3bi DMSO EDTA EGTA ECM F-actin FcR FSC FAK FITC fMLP GAP GDI GDF GDP GEF G-protein GPCR GTP HA HETE HL60 HPETE HRP HSA ICAMs IgG IL-8 LAD LFA-1 LOX LTs arachidonic acid aspirin-triggered lipoxins bovine serum albumine coronary artery disease cyclooxygenase complement receptor 3 (also known as; CD11b/CD18, β2-integrin, Mac-1) C-reactive peptide fragment of complement factor 3 inactivated C3b dimethylsulphoxide ethylenediaminetetraacetic acid glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid extracellular matrix filamentous actin Fc-Receptor forward scatter focal adhesion kinase fluorescein isothiocyanate N-formyl-L-methionyl-L-leucyl-L-phenylalanine, (f-Met-Leu-Phe) GTPase activating protein guanine nucleotide dissociation inhibitor GDI displacement factor guanosine diphosphate guanine nucleotide exchange factor GTP-binding protein G-protein-coupled receptors guanosine triphosphate hemagglutinine hydroxyeicosatetraenoic acid human leukemia 60 hydroperoxyeicosatetraenoic acid horseradish peroxidase human serum albumine intracellular adhesion molecules immunoglobulin G interleukine 8 leukocyte adhesion deficiency lymphocyte function-associated antigen 1 (αLβ2) lipoxygenase leukotrienes 8 LTB4 LX LXa LXA4 MAPK MAPTA/AM MFI NADPH PAF PFA PGs PI-3 K PKC PLA2 cPLA2 sPLA2 PMA PMB PMN PTKs Pyk2 ROS S.E.M. SOD SPT SSC Tat TAT TNF leukotriene B4 lipoxin lipoxin analogue lipoxin A4 mitogen activated protein kinase 1,2-bis-5-methyl-amino-phenoxyl-ethane-N,N,N´-tetraacetoxymethyl acetate mean fluorescence intensity nicotinamide adenine dinucleotide phosphate platelet activating factor paraformaldehyde prostaglandins phospatidylinositol-3 Kinase protein kinase C phospholipase A2 cytosolic PLA2 secretory PLA2 phorbol 12-myristate acetate polymyxin B polymorphonuclear neutrophils protein tyrosine kinases proline-rich tyrosine kinase 2 reactive oxygen species scanning electron microscopy superoxide dismutase single particle tracking side scatter transcriptional activator of transcription of HIV transduction domain of HIV Tat (11 aa) tumour necrosis factor B 9 It was the darkest of times. Evil forces thrived in the world. An enemy invaded the land. But there was hope. The ”White Army” secretly prepared for war on the islands of the Red River. Armed with powerful weapons, they formed the “first line of defence”. Brave soldiers breached the Endothelial Wall in the quest to seek out the vile enemy. The climb in the ECM-Mountains was steep and dangerous. The tracks were easily followed, the foul smell of the invaders lingering in the air. Finally, the enemy camps were in reach. Equipped with deadly toxins, the soldiers attacked. The battle went on for days. Darkness prevailed, but in the end hope returned. Out-numbered, the enemy perished. The land slowly began to heal, and soon no signs of invasion were seen. Once again the inhabitants of the land lived in peace and harmony, knowing that somewhere out there…the quiescent White Army... awaits the next attack... The White Army Enemy Camp Red River Pus-Swamps ECM-Mountains Endothelial Wall 10 11 INTRODUCTION Adhesion The ability to adhere is crucial for many cellular processes. The adhesive interactions are usually transient, but can become static. During embryogenesis, organs are formed by static, homotypic adhesion between cells. In fertilization, the sperm needs to bind to the egg cell for new life to begin. During inflammation, white blood cells (e.g. neutrophils) adhere to, and squeeze between the endothelial cells lining the blood vessels, and seek out invading pathogens. At the site of infection, the white blood cells must adhere to the bacteria in order to engulf them. Many different adhesion receptors are involved in these processes. Cadherins form the static connections between cells. Selectins mediate the initial, loose attachment of neutrophils to the endothelium. Integrins are involved in both firm adhesion to the endothelium, adhesion to extracellular matrix (ECM) during chemotaxis, and during phagocytosis in the adhesion between cells and pathogens during phagocytosis (Fig. 1) (reviewed in (1)). Rolling Firm adhesion Diapedesis Chemotaxis Phagocytosis Endothelium + Selectins Carbohydrates ICAMs Integrins (CR) GPCR C3bi Antibody FcR + + + + + + + + + + + + + + + + + + + 12 + + + + + + + + + + + + + + + + + Figure 1. The inflammatory process. During inflammation, P- and E-selectins are upregulated on the activated endothelium. L-selectins on neutrophils bind loosely to ligands on the endothelial cells, and rolling of the cells on the blood vessel is initiated. Integrins are upregulated on neutrophils upon stimulation with chemokines/chemoattractants or by selectin-mediated rolling (1). Integrins adhere firmly to the endothelium upon binding to ICAMs (reviewed in (2)). After locating “gaps” between endothelial cells, neutrophils, following a gradient of chemoattractants (+), squeeze through the endothelial layer (diapedesis) and migrate towards the site of infection (chemotaxis). Pathogens opsonized with complement factors (C3b/C3bi) or antibodies are engulfed via complement receptor (CR)-mediated or Fc-receptor (FcR)mediated phagocytosis. Reactive oxygen species and enzymes degrade and kill the intracellular pathogens. The actin cytoskeleton Reorganization of the cytoskeleton is an essential process during adhesion, chemotaxis and phagocytosis. Actin filaments form a three-dimensional network called the actin cytoskeleton, which stabilizes the cell. The actin cytoskeleton is remodelled during cell migration, the filamentous-actin (F-actin) being polymerized at the plus (barbed) end, and depolymerized into globular-actin (G-actin) at the minus (pointed) end (Fig. 2). Polymerization of actin is dependent of ATP and monovalent or divalent ions e.g. potassium (K+) and magnesium (Mg2+) (reviewed in (3)). Cellular movement by so called “amoeba-like” migration requires constant turnover of extracellular adhesive contacts, which are intracellularly connected to the cytoskeleton. In order to move the cell body forward, a lamellipodium is extended at the leading edge and attached to the substratum. Simultaneously, the adhesive connections in the back of the cell are disconnected and the cell body is retracted (Fig. 2). 13 A Leading edge Retraction Extention ECM B G-actin F-actin - i) + ii) Figure 2. Cellular migration. A) During migration, the leading edge extends forward and attaches to the extracellular matrix (ECM). In order to retract the cell body, the adhesive connections must be severed at the trailing edge (uropod) of the cell. B) The actin cytoskeleton is composed of monomeric, globular actin (G-actin) i) polymerizing into actin filaments. Polymerization of filamentous actin (F-actin) ii) occurs at the plus end, whereas depolymerization occurs at the minus end of the filaments. Integrins Integrins are transmembrane cell-surface receptors mediating adhesion to the ECM, and to other cells or pathogens. Integrins consist of a α-subunit and a β-subunit, non-covalently bound to each other. Today, 18 α-, and 8 β-subunits have been identified, which can be combined into at least 24 different integrin receptors (4) (Fig. 3), all having a specific function, as shown by the phenotypes of knockout mice (reviewed in (5)). 14 α1* α2* α3 α4 β1 β7 αE* α5 α6 β4 α7 α8 α9 α10 β3 αL* α11 β5 αv β6 αIIb β8 αM* β2 (CD11a/CD18; LFA-1) (CD11b/CD18; Mac-1,CR3, MO-1) αX* (CD11c/CD18, CR4, gp 150/95) αD* (CD11d/CD18) Figure 3. The integrin superfamily. One α- together with one β-subunit constitutes an integrin receptor. Also shown are the alternative designations for β2 integrins. Integrins containing an I-domain are marked with an asterisk. The integrin receptors consist of a large extracellular, ligand-binding domain, a transmembrane domain, and a short cytoplasmic tail (Fig. 4). The CD11/CD18 integrins (β2 integrins), solely expressed on leukocytes, share the same β-subunit combined with four different α-subunits (CD11a, -b, -c, -d). The CD11b/CD18 integrins are the most abundant β2 integrins on neutrophils. In order to participate in cellular processes such as wound healing, cell differentiation, immune responses, and cell migration, the integrins can not be constitutively active. The ligand-binding affinity is closely regulated via conformational changes (Fig. 4) (5). Inactive integrins have a bent conformation, folded at the genu, with the headpiece located 5 nm above the membrane (6, 7). When activated, the unfolded integrins project 20 nm above the membrane, and are accessible for ligand binding (8). It should be noted, however, that ligand binding has been observed already for the “bent” conformation of αvβ3- integrins (9), suggesting that the activation model does not apply to all integrins. 15 Closed, bent formation Closed, extended formation I-domain Intrinsic Ligand Open, extended formation Extrinsic Ligand βI-domain (I-like domain) β-propeller Genu Thigh domain Hybrid domain PSI domain Calf domains α β EGF repeats α β α β Signalling Figure 4. The structure of integrins. The conformational changes in integrins containing an I-domain. In a low affinity state, the α- and β-integrin tails are in a closed, bent conformation. Upon priming (or ligand binding), the integrin receptor ”legs” straighten up in a “switchblade”-like motion (10) and separate; a mechanism associated with increased affinity. The separation of the legs, accompanied by conformational changes allows for binding of cytoplasmic proteins and signalling. Adapted from (6, 1114). Integrin activation: affinity, avidity, and valency Besides the induction of conformational changes of integrins (affinity change), clustering of the receptors on the plasma membrane, together with the association of integrins and the cytoskeleton, are additional ways of activating the integrin receptors (avidity regulation). However, if a conformational change of the integrins is the cause or the result of ligand binding is under debate (15, 16). Changes in affinity and avidity are brought about via an inside out mediated-mechanism, induced by activation of other membrane receptors, e.g. receptors for growth factors, cytokines and chemoattractants. Inside-out signalling, in which the cytoplasmic regions of β2 integrins are key players, is perceived as conformational changes in the extracellular region of the integrins, mediated from the cytoplasmic side by the signal transduction induced by other 16 active receptors. The proteins affecting the inside-out signalling should posses the ability to directly associate with the integrins (Table 1), or be involved in the signal transduction resulting in the activation of integrin-associated molecules (reviewed in (17)). Changes in affinity and avidity put the integrins in a different activation state, so called “primed state”, giving the cells a more “readily activated” character. The terminology surrounding integrin activation is vague. Recently, the term valency has been introduced (14). Valency regulations include changes in the local density, or in the ability of the receptor and ligand to move, which alter the possible number of adhesive bonds that can be formed. Affinity regulations are explained as changes in integrin affinity due to conformational changes. (14). The avidity is considered as the total strength of cellular adhesive interactions resulting from the affinity, valency, and the total number of formed bonds (18). In this thesis, the term valency is not applied, instead affinity and avidity will be used (Fig. 5). 17 Affinity regulation Avidity regulations Upregulation and lateral mobility Clustering Conformational change Connection to cytoskeleton Cytoskeleton Avidity regulation β2 integrins Figure 5. Schematic illustration of integrin activation regulated by affinity and avidity changes. Upon activation, the number of integrin receptors is increased by upregulation from intracellular stores. When the cytoskeletal connections are broken, integrin receptors move laterally on the plasma membrane and form clusters, thereby accumulating the number of low-affinity binding integrins in one area, resulting in increased binding/adhesion. The ligand binding of integrins can also be strengthened by altering the connection between receptors and the cytoskeleton. Affinity is increased by a conformational change in the integrin receptor, resulting in augmented ligand binding. β2 integrin ligation Besides being adhesion receptors, integrins cross-talk with other receptors on the plasma membrane, and transmit signals into the cell interior. The extracellular domain of β2 integrins binds to the ECM, or to counter receptors on neighbouring cells. The cytoplasmic domain interacts with cytoskeletal proteins, forming a physical link between ECM and the cytoskeleton, thereby regulating the signalling capacity of the receptor. Ligation of the receptor induces a signal that propagates within the cell, a process called outside-in signalling. For example, besides inducing the activation of adhesion kinases localized to focal complexes, ligation of integrins can activate mitogen activated protein kinase (MAPK), GTPbinding proteins (G-proteins), polymerization of F-actin, and induce release of Ca2+. 18 ICAM-1, was one of the first molecules to be identified as a ligand for leukocyte integrins (19). ICAMs belong to the immunoglobulin superfamily consisting of five members: ICAM 1-5 (reviewed in (20, 21)). In addition to ICAMs, β2 integrins bind a vast number of molecules including; fibrinogen, collagen I, and C3bi. In T-cells, the binding of soluble ICAM (sICAM), corresponding to increased integrin affinity, is induced by divalent ions such as Mg2+ and Manganese (Mn2+) (16, 22), (23). The integrin receptors contain multiple binding sites for calcium (Ca2+) in their extracellular domains, and Ca2+ is another ion regulating integrin activation/ligand binding. Surprisingly, Ca2+ has a dual role in both inducing adhesion, by integrin clustering (24), and inhibiting adhesion. Actually, Ca2+ has to be removed in order for Mg2+ to induce changes in affinity (23). Table 1. A summary of proteins interacting with integrin cytoplasmic domains. Adapted from (25). Protein Integrin tail References Filamin β1A, β2, β7 (26, 27) Talin β1-5, αIIb, (β7) (26, 28) α-actinin β2, β1 (29) Radixin β2 (30) CIB αIIb (31) Calreticulin α (32) FAK (p125) β (33) ILK (p59) β (34) Pyk2 β2 (35) Paxillin β1, β2, β3, α4, α9 (33, 36, 37) Cytohesin-1, and -3 β2 (38) β3-Endonexin β3 (39) ICAP-1 β1 (40, 41) Rack1 β1, β2, β3 (42) Eps8 β1a (43) PI3 Kinase β1 (44) IRS-1 αvβ3 (45) Phospholipase Cγ β1 (46) 14-3-3 β β1 (47) Annexin-V β5 (48) 19 Integrins, partners in sickness and in health Leukocytes are key players in inflammation and thereby also potential targets for antiinflammatory drugs. Normally, non-adherent leukocytes circulate in the blood, become activated, and transmigrate through the endothelium into the tissues. Unregulated accumulation of leukocytes in target organs or tissues may result in diseases such as asthma, rheumatoid arthritis, atherosclerosis, multiple sclerosis and Crohn’s disease. Moreover, the elevated number of neutrophils in circulation increases the risk of developing cardiovascular disease. Data from patients with leukocyte adhesion deficiency (LAD) and integrin knockouts, confirm the central role of integrin signalling during inflammation. LAD-I is an inherited immunodeficiency in which the expression of β2 integrins is diminished or lost (49). LAD patients suffer from impaired inflammatory responses, defects in T cell proliferation, and skin infections (reviewed in (5)). Other LAD deficiencies have been identified, where the expression of β2 integrins is normal, but the function is impaired, probably due to defective “inside-out signalling” (50, 51). In the last decade, neutrophils have been identified as active participants in the inflammatory process of atherosclerosis, which in turn is a major risk factor in the development of coronary artery disease (CAD). 20 Integrins, matrix adhesions and associated proteins Integrins and their binding partners (summarized in Table 1) are organized in multi-protein complexes termed “matrix adhesions”. They are highly dynamic and difficult to study as isolated organelles. The matrix adhesions include focal complexes, focal adhesions (also designated focal contacts), fibrillar adhesions and podosomes (52). Focal complexes are small (100 nm), dot-like structures usually concentrated in membrane protrusions of migrating cells. Focal complexes can mature into larger focal adhesions (1 μm) found mainly in resting cells or in areas with low motility (52). Fibrillar adhesions are formed in cells adhering to fibronectin via α5β1, and do not contain vinculin or paxillin (53). Podosomes are formed in osteoclasts or cells of hematopoietic origin e.g. neutrophils (54-56). Cytoskeletal proteins associated with adhesion complexes Talin was the first protein identified as a cytoplasmic binding partner to integrins (28). Talin is a cytoskeletal protein that participates in the activation of integrins, formation of adhesion matrices, in connecting integrin receptors to the cytoskeleton (reviewed in (57)), and in β2 mediated phagocytosis (58). Talin binds with high affinity to the cytoplasmic tails of β integrins via the N-terminal, FERM (i.e. protein 4.1, ezrin, radixin, moiesin) domain (26), and to actin via the C-terminal domain. Recently, an alternative splicing product of talin, talin2, has been identified (59). The function of talin2 remains to be elucidated. In neutrophils, the connection between CD11a/CD18 and talin is disrupted upon activation, following an association of the integrin receptors with α-actinin (60), the cytoskeletal protein that crosslink F-actin. Paxillin is another adaptor protein important for the assembly and functions of matrix adhesions. Paxillin, together with talin, is one of the first proteins recruited to focal contacts (61). Rho GTPases and cytoskeletal rearrangements The regulation of the cytoskeletal rearrangements induced by chemoattractants is mediated by the family of small GTPases. In neutrophils, research has mainly focused on the members Rho, Rac, and Cdc42, which become transiently activated by N-formyl-L-methionyl-L-leucylL-phenylalanine (fMLP) (62-65). The transition of the GTPases between inactive, GDPbound and active, GTP-bound state is regulated by guanine nucleotide exchange factors 21 (GEFs), and GTPase activating proteins (GAPs) (reviewed in (52)). GEFs catalyze the exchange of GDP for GTP during activation of the GTPases, and GAPs stimulate the low intrinsic hydrolytic activity (Fig. 6). The activation of GTPases is further regulated by guanine nucleotide dissociation inhibitors (GDIs) which prevent exchange of GDP to GTP, and hence must be dissociated from the GTPases during activation (66). GEF Active Rho GTPase Inactive Rho GTPase P GD GAP G TP I GD GDF GDI Figure 6. The activation model of Rho GTPases. The transition between active/inactive state is modulated by guanine nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs), and guanine nucleotide dissociation inhibitors (GDIs). The dissociation of RhoGDI and RhoGTPase is mediated by GDI displacement factors (GDFs). Post-translational lipid modifications at the C-terminal part target the GTPases to different membranes/compartments (67), thereby exerting different effects on the cytoskeletal rearrangements. In neutrophils, Rac is located in the front of the cells, mediating the formation of leading edge and F-actin assembly (68, 69). The primary role of Rac is to induce protrusive force during cell motility. Integrin ligation induces the translocation of inactive Rac and Cdc42 from the cytoplasm to the membrane, and mediates the dissociation of RacGDI (70). β2 integrin-ligation activates Rac and Cdc42 in neutrophils (71), and both Rac and Cdc42 are translocated to the plasma membrane in an integrin-dependent manner (70). Cdc42 localizes to the leading edge of chemoattractant-stimulated neutrophils, and becomes activated by p21-activated kinase (PAK) and the RacGEF, PIXα. Rho regulates myosin IImediated retraction of the tail in monocytes and neutrophils through its effector Rho kinase 22 (ROCK) (72, 73). Rho-H has been proposed to negatively regulate CD11a/CD18 avidity (74). Rac and Rho are concentrated in lipid rafts (75), (76), and Rac co-localizes strongly with GM1 (77, 78). Rap1 and RAPL Recently Rap1, a small GTPase belonging to the family of Ras-like GTPases has emerged as an important regulator of integrin-mediated adhesion (79). Activated Rap1 induces increased affinity and clustering of CD11a/CD18 in lymphocytes (80). Rap1 also regulates the interaction between talin and integrins (81). In macrophages, Rap1 regulates complementmediated phagocytosis (82). Using yeast-two-hybrid screening, the Rap1-binding proteins RAPL and Riam (Rap1-interacting adaptor molecule) have been identified (83-85). RAPL is highly expressed in lymphocytes, and associates with the GTP-bound Rap1. Both RAPL and Riam contain Ras-association domains but their function needs to be elucidated. Proteins involved in mediating signal transduction induced by integrins The protein tyrosine kinases Plasma membrane receptors lacking intrinsic protein tyrosine kinase activities, i.e. integrins, recruit non-receptor tyrosine kinases in order to mediate signals (86-92). The focal adhesion kinase (FAK) belongs to the family of non-receptor tyrosine kinases and plays a central role in integrin-mediated signalling (93). The FERM domain, located at the N-terminus of FAK, binds β1 integrin cytoplasmic tails. At the C-terminus, FAK contains a focal adhesion targeting (FAT) domain functioning as binding site for talin (94), paxillin (95) and p190RhoGEF (96). FAK-mediated tyrosine phosphorylation of Y12 in the α-actinin binding domain negatively regulates the interaction between α-actinin and actin (97). FAK-deficient cells show delayed spreading, reduced adhesion turnover (98), as well as decreased Rac activity and loss of lamellipodia (99, 100). Over-expression of FAK on the other hand, increases the directional motility of cells (101). Another member of the of non-receptor tyrosine kinase family is the proline-rich tyrosine kinase 2 (Pyk2; also designated CAKβ, RAFTK, FAK2, or CADTK) identified in 1995 23 (88-91). Pyk2 and FAK share high overall amino acid identity (48%) (102), and display 60% identity in the catalytic domain, 31% in the N-terminal part, and 45% at the Cterminus (102). Pyk2 is expressed mainly in the central nervous system and in cells of hematopoietic origin (35, 103, 104). Two spliced isoforms of Pyk2 have been described, characterized by the presence or absence of an exon coding for a 42 amino acid insert in the C-terminal region (105, 106). Pyk2-H, the spliced variant lacking the exon, is expressed in hematopoietic cells, and the unspliced form is predominant in the brain (105). FAK has been detected in cell lysates of human neutrophils although it does not appear to be activated by cell adhesion in these cells (107, 108). Differentiated HL60 cells do not express FAK (35). These data suggest that FAK has a less certain role in integrin signalling in human neutrophils/HL60 cells (109), and we therefore propose Pyk2 to be the focal adhesion protein tyrosine kinases involved in integrin mediatedsignal transduction in these cells. The central catalytic domain of Pyk2 is flanked by non-catalytic regions on both sides. The major autophosphorylation site is Tyr-402 in the N-terminal domain, which acts as a binding site for the SH2 domain of Src (110). The activation of Pyk2 occurs in multiple steps. The initial autophosphorylation of Tyr-402 (88, 111) mediates binding of Srckinases which in turn phosphorylate Tyr-580, thereby enhancing the enzymatic activity of Pyk2 (112, 113). The proceeding phosphorylation of Pyk2 involves both Srcdependent and independent signalling pathways (110, 111, 114). The C-terminal domain of Pyk2 contains two proline-rich motifs that function as sites for SH3-mediated proteinprotein interactions (115-120). Several proteins associate with Pyk2, including the focal adhesion proteins; paxillin (121), and p130Cas (122), Src-kinases (102), the ARF-GAP protein PAP (123), and the Nirs (124). Thus, Pyk2 not only functions as a link between heterotrimeric G-protein-coupled receptors and signalling pathways (125, 126), but also has an essential role in the transfer of signals from the adhesion receptors to regulators of the cytoskeleton, i.e. serves as a scaffold in the formation/activation of focal complexes. 24 Cell motility The capacity of cells to sense changes in the external environment during migration towards a gradient of chemotactic substances (i.e. chemotaxis), is essential in inflammation. Neutrophils are one of the fastest moving cells; migrating up to 10- 20 μm per minute, and represent a good model system for investigating chemotaxis. Chemotaxis is initiated by binding of chemoattractants to G protein-coupled receptors (GPCRs). GPCRs belong to a large family of seven transmembrane spanning receptor proteins that activate intracellular heterotrimeric G proteins consisting of α-, β-, and γ-subunit. Upon activation, the GDP bound to the α-subunit is exchanged for GTP. GTP induces to dissociation of the β/γ and α subunit, and regulates down-stream effectors, thereby amplifying the signal (Fig. 6). The chemoattractants inducing chemotaxis are N-formyl-L-methionyl-L-leucyl-L- phenylalanine (fMLP) released by bacteria, the arachidonic acid metabolite leukotriene B4 (LTB4), complement factor 5a (C5a), platelet activating factor (PAF), and the chemokine interleukin-8 (IL-8) (127). A hierarchy exists between the different chemoattractants in their potency of inducing chemotaxis, where end-target chemoattractants e.g. fMLP are more potent compared to intermediary chemoattractants e.g. IL-8. In a milieu of different chemotactic gradients, the cells will favour end-target before intermediary chemoattractants (128). Moreover, different signalling pathways are activated by intermediary, versus endtarget chemoattractants during neutrophil chemotaxis. The chemotactic response to end-target chemoattractants involves p38 MAPK and CD11b/CD18, whereas the signalling pathways activated by intermediary chemoattractants are dependent on PI-3K and CD11a/CD18 (128, 129). 25 GPCR α γ GTP β ? PLC Rho GTPases (Rho, Rac, Cdc42) PI 3K MAPK Tyrosine kinases (Pyk2, Syk, Src) PIP2 IP3 DAG PIP2 PIP3 Calcium ↑ PKC Figure 7. The signalling pathways activated by heterotrimeric G-proteins. Chemoattractants, binding to seven transmembrane spanning, G protein-coupled receptors (GPCRs), activate heterotrimeric G proteins. Upon GTP binding, the α- and β/γ-subunits dissociate and mediate the activation of downstream effector proteins. Adapted from (130). Regulation of adhesion signalling by lipid metabolites Phosholipase A2 To date, 22 genes encoding different phospholipase A2 (PLA2) proteins have been identified in mammals (131). The superfamily of PLA2 can be divided, according to their biochemical properties into 4 subfamilies: i) the Ca2+ -dependent secreted enzymes (sPLA2), ii) the Ca2+dependent cytosolic enzymes (cPLA2), iii) the Ca2+-independet cytosolic enzymes (iPLA2), iv) and the platelet-activating factor acetyl hydrolases (PAF-AH) (132). It is generally accepted that the activity of PLA2 is regulated by phosphorylation. Several kinases regulate the activity of PLA2, including PKC and MAPK (133). The plasma level of sPLA2 is increased in patients with inflammatory or autoimmune diseases such as rheumatoid arthritis, septic shock, Crohn’s disease, and ulcerative colitis. In 26 neutrophils, the group IIA sPLA2 stimulates release of LTB4 (134), and increases the expression of CD11b/CD18 by promoting translocation from secretory vesicles to the plasma membrane (135). The unique trait for iPLA2 is the lack of requirement for calcium for their enzymatic activity. iPLA2 is involved in regulation of cell physiology and metabolic homeostasis, but is not a major player in inflammatory processes (136). Instead cPLA2 and sPLA2 appear to be important for induction of inflammation. Arachidonic acid and pro-inflammatory eicosanoids In addition to regulation by protein-protein interactions, the signalling pathways mediated in adherent and migrating leukocytes are heavily influenced by lipid mediators. Lipid mediators have been found to enhance the β2-integrin mediated adhesion to fibrinogen and C3bi (137). Moreover, β2-mediated phagocytosis induces the release of arachidonic acid (AA) (138). Arachidonic acid is a polyunsaturated fatty acid hydrolyzed by PLA2 from the sn-2 position of glycerophospholipids (139). Upon release, arachidonic acid per se can influence cellular processes, e.g. actin bundling (140), degranulation, and superoxide production (141), or become metabolized by either cyclooxygenases (COX) to prostaglandins and thromboxanes, or by lipoxygenases (LOX) to form leukotrienes and lipoxins. The oxygenation of arachidonic acid by 5-LOX, results in the formation of 5-hydroperoxyeicosatetraenoic acid (5-HPETE), a precursor for leukotrienes and lipoxins (Fig. 8). Various eicosanoids (AA metabolites, e.g. 5LOX metabolites), can regulate cell adhesion, as well as other processes involving cytoskeletal reorganization (142, 143). Activation of PLA2 and AA per se, increase the expression of β2-integrins on the plasma membrane of neutrophils (144). cPLA2 and AA have also been shown to regulate the superoxide production in phagocytes (145, 146). In addition, the arachidonic acid binding protein S100A8/A9, has been identified as a novel binding partner for the NADPH-oxidase subunits p67phox and Rac (146). 27 PLA2 Lyso-PAF COOH AA PAF 5-LOX 5-HETE COX-2 5-HPETE PGH2 12-/15-LOX LX LTs PGs TXs Figure 8. The arachidonic acid metabolism. Arachidonic acid (AA) is hydrolyzed by phospholipase A2 (PLA2) at the sn-2 position of glycerophospholipids. The lysophospholipid formed can be metabolized into platelet activating factor (PAF). AA is metabolized via the cyclooxygenase (COX) pathway to prostaglandins (PGs) and thromboxanes (TXs), or via lipoxygenase (LOX) pathways to leukotrienes (LTs), and lipoxins (LX). Anti-inflammatory lipoxins Lipoxins are eicosanoids derived during a transcellular process by the combined action of 5LOX, and 12-LOX or 15-LOX (147). Lipoxins function as innate “stop signals” that control inflammation processes (148) mainly by inhibiting the chemotactically induced signalling pathways. Lipoxins inhibit the LTB4 and fMLP-induced chemotaxis (149), adhesion and transmigration (150), expression of β2 integrins on neutrophils (151), and cytokine formation (152). Lipoxins bind to G-protein-coupled seven-transmembrane spanning receptors. The lipoxin receptor (ALX) belongs, together with fMLP- and LTB4-receptors, to the same cluster of GPCRs (153). In the presence of aspirin 15-epi lipoxins are formed, which are more potent than the native lipoxins (153). Due to the rapid conversion of lipoxins to inactive compounds (154), stable 28 lipoxin analogues (LXa) have been synthesized (155). These analogues are almost as potent as the aspirin-triggered lipoxins (ATL) (reviewed in (156)), and are therefore useful tools in elucidating the signalling pathways induced by adhesion and chemotactic stimuli. The lipoxin analogues inhibit PMN transmigration across epithelia and block PMN adhesion (155). Lipoxins redistribute myosin IIA and Cdc42 in macrophages, and are implicated to regulate phagocytosis and apoptosis (157) in a non-phlogistic manner. Phagocytosis Phagocytosis is defined as cellular engulfment of particles larger than 0.5 μm. Professional phagocytes are cells mainly focusing on phagocytosis i.e. neutrophils, eosinophils, basophils, monocytes, and macrophages. In order for phagocytosis to take place, the cells must first localize, recognize and bind the particle. Recognition is mediated via specific receptors on the plasma membrane. Two sets of receptor types are activated during phagocytosis, namely Fcreceptors (FcR) and complement receptors (CR) both mediating distinct signalling pathways. Particles opsonized with IgG-antibodies are captured and engulfed by FcγR located on Factin-containing protrusions called pseudopodia. FcγR-mediated phagocytosis is dependent on Ca2+ and actin reorganization. The FcγR-mediated signalling cascade involves the activation of various proteins including: PLC, PKC, PI-3K, Rac, Cdc42, PLA2 and MAPK (reviewed in(158)). The CR-mediated phagocytosis on the other hand, does not involve active formation of pseudopodia and is thus less dependent on calcium. The complement receptor 3 (CR3), identical to CD11b/CD18 integrin, binds C3bi-opsonized particles. An early event in CRmediated phagocytosis is tyrosine phosphorylation and activation of proteins such as: paxillin, RhoGTPases, Pyk2, PLC, and vav (103, 107, 121, 159, 160). The phagocytic process Besides adhesion, migration, and aggregation, the phagocytic process also includes engulfment of the particle, degranulation and bacterial killing. Killing of microorganisms located in the phagosome, involves generation of reactive oxygen species (ROS) including superoxide anion produced by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Superoxide anion produced by NADPH-oxidase, is converted by superoxide 29 dismutase (SOD) and catalase to H2O2 and H2O. In the presence of myeloperoxidase and chloride, H2O2 forms the toxic hypocloric acid. NADPH-oxidase consists of several membrane associated and cytosolic components, one of them being the RhoGTPase Rac (161). Cdc42 has emerged as a competitor of Rac2 for the binding to NADPH-oxidase (162, 163). The actin cytoskeleton plays an important role in regulating the assembly and stabilization of the NADPH-oxidase (164, 165). Assembly of NADPH-oxidase occurring at the membrane of intracellular components induces intracellular ROS production, whereas activation of NADPH-oxidase at plasma membrane leads to extracellular release of ROS. Degranulation Neutrophils are equipped with vesicles containing proteolytic enzymes and bactericidal peptides to combat ingested bacteria. Four populations of granules are found in neutrophils namely i) primary (azurophil) granules, ii) secondary (specific), peroxidase negative granules, iii) tertiary gelatinase granules, and iv) secretory vesicles (reviewed in (166)). The different granules are mobilized following a hierarchy, and differ in aspects of content and function. The azurophilic granules contain for example myeloperoxidase, defensins, lysozymes, and CD63. Certain receptors are also stored in granules and are upregulated upon stimulation. The β2 integrins and receptors for fMLP and IL-8, localize to specific granules and/or secretory vesicles (166). HL60 cells lack specific granules and the upregulation of for example β2 integrins is therefore impaired (167). Translocation of granules, and fusion with phagosome is mediated by both the actin- and microtubulin network (168). The internalization of the particle induces polymerization of F-actin at the site of ingestion. The F-actin surrounding the phagosome must be degraded to allow endosome/lysosome to fuse with the phagosomal membrane. Proteins implicated in the phagosomal maturation are SNAREs, rab 5, rab7, and PKC (166, 168). Despite being activated during phagocytosis, neither Rac nor Cc42 has been found to localize to the plasma membrane in their active form. Since small GTPases regulate actin turnover, the involvement of activate Rac and Cdc42 in phago-lysosomal formation could be expected. 30 AIMS OF THE INVESTIGATION The aim of this thesis was to shed light on the regulation of the β2 integrin-mediated signalling in human neutrophils. To achieve this, pro- inflammatory (i.e. fMLP, IL-8 and LTB4) substances, and anti-inflammatory endogenous- (i.e. lipoxin, epi-lipoxin), and exogenous substances (i.e. statin, aspirin) were employed. The more specific aims were to understand: i) The regulatory effect of pro- and anti-inflammatory substances on the β2 integrinactivation state (avidity vs. affinity) of human neutrophils from healthy donors and from patients suffering from coronary artery disease (CAD). Statin β2 integrins LTB4-R fMLP-R IL-8-R ? LXA4-R ii) Aspirin The regulatory effect of the pro- and anti-inflammatory substances, on the signalling capacity of β2 integrins (i.e. the release of AA, and production of ROS), in healthy donors and in patients suffering from coronary artery disease (CAD). 31 + aspirin, lipoxin, statin ? β2 pansorbin fMLP LTB4 ? ? AA ROS iii) The effect of the pro- and anti- inflammatory substances on the β2 integrin-mediated signal transduction (phosphorylation of Pyk2) in neutrophils. + aspirin, lipoxin ? β2 pansorbin fMLP LTB4 ? ? Pyk2 iv) P In addition, the aim was to establish methods for investigating the proteins involved in the regulation of β2 integrin-mediated signalling, e.g. western blot, immunoprecipitation, immunofluorescence, single particle tracking, and TATtransduction. 32 METHODS Some of the methods used in this thesis will be discussed briefly herein. Neutrophils When studying blood cells, different approaches are available. One is to use freshly isolated neutrophils from blood donors. The limited usage of neutrophils lies in the availability of the cells and in the limited life span of the neutrophils once isolated from whole blood. The status of the blood cells from donors can also vary between experiments, due to individual donor differences. Moreover, the neutrophils are affected by the isolation procedure, and the use of whole blood is therefore preferable for some assays. However, when interpreting the results, one must keep in mind that the different cell types in whole blood could influence each other. In his study, whole blood was used when analyzing neutrophils from patients suffering from stable Coronary Artery Disease (CAD), due to the limitation in blood sample volumes. Thirty patients with angiographically verified stable CAD were recruited. Each patient was matched, regarding age and gender, with a clinically healthy control subject, randomly selected from the population register. Patients were excluded if they were >65 years old, had severe heart failure, immunologic disorders, neoplasm disease, evidence of acute or recent (<2 months) infection, recent major trauma, surgery or revascularization procedure, or treatment with immunosuppressive or anti-inflammatory agents (except low-dose aspirin). Another approach when studying neutrophils is to use commercially available cell lines, which can be differentiated into neutrophil-like cells. The cells have a more stable phenotype compared to freshly isolated neutrophils. However, the tumour cells may have some inherent defects. In this thesis, we have used both freshly isolated human neutrophils, and a promyelocytic cell line i.e. Human Leukemia 60 (HL60). The HL60 cells can be differentiated into neutrophils, monocytes and macrophages depending on the differentiation agent used. When grown in suspension in the presence of DMSO for 6-7 days (169), the HL60 cells become neutrophil-like and acquire the ability to adhere, migrate, and 33 phagocytose like the peripheral blood neutrophils. Neutrophil-like HL60 cells do not contain specific granules and lack the ability to up-regulate some receptors on the plasma membrane. This can be used as tool when studying certain cellular processes in neutrophils, such as the activation state (affinity /avidity) of β2 integrins. [3H]arachidonic acid-labelling and release To investigate the role of lipid mediators in β2 integrin signalling, the cells were incubated with [3H]labelled arachidonic acid ([3H]AA). Isolated neutrophils were incubated for 2h at 37°C, whereas HL60 cells were labelled for the final 18-24 hours of the cell-differentiation period. During the experiments, human serum albumin (HSA) was added in order to trap the released fatty acids and prevent further metabolism (170). The reaction was stopped by centrifugation and the radioactivity of the supernatant was measured in a β-counter. Cell stimulation Activation by chemotactic factors During inflammation, neutrophils navigate along a gradient of chemotactic factors e.g. fMLP, LTB4, and IL-8. fMLP is an end-target chemoattractant released by the bacteria at the site of infection, and is considered more potent than the endogenously formed intermediary chemoattractants LTB4 and IL-8 (128). In this study, the effect of intermediary- and end target chemoattractants on β2 integrin signalling was investigated both in differentiated HL60 cells and in human neutrophils from healthy donors and CAD patients. Integrin ligation Activation by antibody-coated Pansorbins® The pansorbins® are heat-hardened Staphylococcus aureus, expressing protein A on the surface. The Fc-part of the antibody will bind to protein A, giving rise to a pansorbin particle coated with antibodies exposing the Fab-part outwards, in contrast to opsonized particles (Fig. 9). By using pansorbins, receptors on the plasma membrane of cells kept in suspension can be directly activated without the interference from other adhesion receptors. This is a good model system for β2 integrin ligation, since the particles do not mediate spreading or 34 phagocytosis. One advantage of using Pansorbins® is that the unspecific antibody-interactions are reduced, since the Fc-part of the antibody is coupled to the Pansorbin® and can not interact with Fc-receptors. A B Intracelullar signalling Phagocytosis and signalling Figure 9. A) The difference between antibody-coated and antibody-opsonized particles. Anti-β2 integrin antibodies coupled to pansorbins® interact with β2 integrin receptors via their Fc-part, giving rise to receptor mediated signalling. B) Pansorbins® opsonized with IgG antibodies are recognized by the receptors through the Fc-part of the antibody, inducing Fc receptor-mediated phagocytosis and subsequent signalling. Integrin ligation in adherent cells In order to verify the results observed by anti-β2 integrin-pansorbins, cells were allowed to adhere to the β2-integrin ligand, fibrinogen. Using the adhesion assay enabled us to study the signalling pathways induced by β2 integrin ligation and reorganization of the cytoskeleton, and to elucidate the need for “cellular priming”, i.e. integrin activation, prior to adhesion. As a control, cells were plated on BSA-coated culture dishes. Flow cytometry Flow cytometry is a quantitative approach, used to analyze the total fluorescence of individual cells/particles ranging from 0.5 μm to 40 μm in size, in a single cell suspension. Intracellular molecules and membrane markers can be stained with different fluorochromes and analyzed simultaneously in the flow cytometer (Fig. 10). The cells pass through a light source one at a time. Light is scattered upon passing through the cells and the fluorochromes are exited to a 35 higher energy state. This energy released in form of emitted light, is detected together with the scattered light by several detectors. Light passing through the cells is detected as forward scatter (FSC) and is relative to the cell size. The more granular the cells, the more the light is scattered to the sides, detected as side scatter (SSC). By plotting FCS against SSC, different cell populations can be visualised and a region of interest established, so called gating. Therefore, when analyzing different blood cells by flow cytometry, whole blood can be analyzed directly in the flow cytometer. The cell population of interest is then visualized in a frequency histogram and the mean fluorescence intensity (MFI) can be analyzed by statistics. B SSC A Dot Plot Region of interrest (gating) Detectors Laser FSC Forward scatter (FSC = cellular size) Fluorescense Number of events (FL1) Side scatter (SSC = granularity) Frequency histogram for the population MFI FL1 Movement of the curve to the right is equivalent to an increase in MFI Figure 10. The principles of flow cytometry. In brief; cells suspended in a carrier solution, pass a light source one at a time, and the fluorochromes become excitated to a higher energy state. The light emission is detected together with the scattered light, enabling the selection of a region of interest (i.e. gating). Fluorescence (FL1) is plotted in a frequency histogram and the mean fluorescence intensity (MFI) is calculated for the selected population. In this study, the FITC-fluorescence of individual cells was determined by flow cytometry, using a Becton Dickinson FACSCalibur (Becton Dickinson, San Jose, CA/USA). Mean 36 fluorescence values, from a minimum of 5000 cells/ sample, were determined. Gating was performed by using forward scatter versus side scatter (excluding cell debris). Autofluorescence of unstained cells was routinely analyzed and subtracted from the fluorescence values of the stained cells. Unspecific binding was analyzed by isotype antibodies. Expression of β2-integrins Prior to investigating the activation state of the β2 integrins, it was important to quantify the number of integrin receptors on the plasma membranes of HL60 cells. If no receptors are upregulated upon stimulation, increased integrin affinity should be due to an activation of β2 integrins and not be dependent of an increased number of receptors on the plasma membrane. In brief: Cells were pre-incubated with anti and pro-inflammatory stimuli alone or in combination. Stimulation was stopped by ice-cold PFA, washed and incubated with primary anti-CD18 antibodies, followed by incubation with secondary, FITC-conjugated antibodies. In human neutrophils, β2 integrins are stored in granules and become expressed on the membrane upon stimulation. The basal expression of β2 integrins on human neutrophils from healthy donors and CAD patients was therefore investigated. Due to limitations in blood volume from patients, the flow cytometry assay was adjusted by analysing neutrophils from whole blood. β2 integrin affinity One way of investigating the activation state of the integrins is to measure affinity of the integrin receptors. Two high-affinity antibodies; CBRM 1/5 and MAb24 were used in this study. CBRM 1/5 is a monoclonal antibody recognizing the ligand binding domain (i.e. Idomain) on CD11b integrins (171), whereas MAb24 recognizes a high affinity epitope on the α-subunit of both the CD11a and CD11b integrins (172). In order to measure affinity of β2 integrins, the antibodies had to be present prior to stimulation of the cells, probably due to destruction of the recognition epitopes by PFA. The cells were pre-incubated with the CBRM 1/5 antibody for one minute prior to stimulation, fixed in PFA and incubated with FITC- 37 conjugated secondary antibodies. Alternatively, a FITC-conjugated CBRM 1/5 antibody was used. Binding of soluble ICAM-1 The β2 integrin-ligand ICAM-1, binds to the receptor when the ligand binding domain is exposed upon increased affinity. In order to verify the results obtained by the high affinity antibody with a more biological read-out, we investigated the binding of soluble ICAM-1 (sICAM) to the β2 integrins (173) by flow cytometry. Fluorescence microscopy The fluorescence microscope was used to evaluate the lateral movement of β2 integrins during the Single Particle Tracking experiments, and to analyze the distribution of F-actin in HL60 cells during phagocytosis. In contrast to flow cytometry, which gives the total amount of fluorescence in a cell, the fluorescence microscope can be used to determine the distribution of fluorescence in the cell. Single Particle Tracking The Single Particle Tracking (SPT) technique was used to measure the movement of individual β2 integrins on the plasma membrane of neutrophils. By conjugating β2 integrinspecific antibodies to fluorescent latex beads (174), the lateral movement of integrin receptors can be monitored in a fluorescence microscope (Fig. 11). In short: neutrophils were plated on poly-L-lysine-coated cover slips and stimulated. The movement of individual antibodyconjugated beads was recorded for 30 seconds and the diffusion coefficient (D) was calculated. 38 Membrane receptor Fluorescent latex bead (conjugated with a receptor specific antibody) Lateral movement of receptors Analysis in a fluorescence microscope = Diffusion Coefficient (calculated by software) Figure 11. The principles of the single particle tracking method. Cells are stimulated and allowed to settle on poly-L-lysine coated cover slips. The cells are incubated with specific antibodies conjugated to fluorescent latex beads, and movement of the fluorescent particles is monitored in a fluorescence microscope. The diffusion coefficient, equivalent to lateral movement of the receptor, is determined by computer software. Confocal Scanning Light Microscopy By using Confocal Scanning Light microscopy (CSLM), the fluorescence from a thin optical section in a cell (a focal plane) can be analyzed. In contrast to ordinary fluorescence microscopy, CSLM gives a high resolution image of a chosen focal plane in a cell, simultaneously eliminating the light coming from out-of-focus regions above and below that plane. CSLM was used to analyze clustering of β2 integrin receptors on the plasma membrane, the actin distribution around the phagosome, and the distribution of CD63-positive granules in HL60 cells. 39 Image analysis To analyze the results obtained by CSLM different imaging analysis procedures were used. Clustering of integrins In order to quantify the size of the integrin clusters from a confocal microscope image, the β2 integrins on individual cells were traced manually. The fluorescence was plotted as a histogram in which the peaks were equivalent to clusters of integrins. This allowed us to quantify the number of small and large peaks i.e. small/large β2 integrin clusters. Granule distribution The effect of TAT-proteins on the distribution of CD63 positive granules was analyzed by CSLM. To more objectively evaluate granule movement in living cells, confocal microscope images of cells loaded with LysoTracker®Red DND 99 were analyzed. Software was used to evaluate the accumulation-, number-, and distribution of granules in the cells. Introduction of recombinant proteins into human neutrophils Transfection is a method used to introduce recombinant DNA into cells using eukaryotic expression vectors. The most common transfection methods are electroporation, liposomebased transfection (e.g. Lipofectamine), retroviral gene transfer, cationic polymer-based system (e.g. DEAE-dextran), and the use of chemicals such as CaPO4 (175, 176). DNA can also be directly injected into a cell, by so called microinjection. When working with neutrophils, one quickly discovers the obstacles lying ahead. Neutrophils have a limited life span, and contain granules filled with degrading enzymes. The production of stable transfectants is therefore impossible. To circumvent this, cell lines can be used for transfection. Initially in this project, efforts were made to transfect neutrophils and HL60 cells by various transfection approaches (i.e. electroporation, DEAE-dextran, retrovirus, and lipofectamine) without success, hence other methods to introduce recombinant proteins were established. 40 HIV Tat proteins The human immunodefiency virus-1 (HIV-1) contains a transcriptional activator of transcription (Tat) necessary for the replication of the virus (reviewed in (177)). In 1988, it was shown that the HIV-tat protein (86 amino acids) could cross cellular membranes and accumulate in the nucleus and induce gene activation (178, 179). Different molecules linked to Tat, e.g. FITC, DNA and proteins, translocate along with the Tat-peptide into the cytoplasm. The uptake of tat-proteins into the cell remains unclear, but is proposed to take place via a receptor/transporter- and endocytosis- independent pathway. Tat-proteins have also been suggested to directly penetrate the membranes (180), via a process facilitated by, but not dependent of, denaturation and refolding of the proteins (181, 182). Nevertheless, Tat-mediated protein transduction has emerged as a useful tool to insert molecules into cells, in which transfection protocols are not applicable. TAT transduction In this study, we used a pTAT- HA vector (181) containing an amino-terminal, transduction domain of HIV Tat (11 aa), termed TAT. The pTAT-HA vector contains the gene for six histidines (used for affinity purification) and a hemagglutinine (HA) epitope (used for detection of transduced proteins) linked to a TAT-sequence, followed by a multiple cloning site (Fig. 12). Initially, human neutrophils were transduced with TAT-fusion proteins, but due to rapid degradation of the proteins, differentiated HL60 cells were used instead. After optimization of the transduction conditions, the cells were transduced with 200 nM TATfusion proteins for 30 min at 37ºC in calcium free-KRG. The transduction efficiency was 65% or more. YGRKKRRQRRR Figure 12. Characterization of the pTAT-expression vector. The pTAT-HA vector contains six histidines (His6), followed by 11 amino acid transduction domain of HIV-Tat (TAT), and a hemagglutinine (HA) epitope linked to a multiple cloning site (MCS). Adapted from (181). ATG-His 6-TAT-HA-MCS pTAT-HA 41 Immunoprecipitation and Western blot When studying activation of intracellular proteins different approaches can be used. The first step involves mechanical (e.g. sonication, homogenization), or chemical (e.g. Triton-X 100, saponine) disturbance of the plasma membrane integrity in order to access the intracellular proteins. The proteins of interest can be “fished out” by specific antibodies conjugated to sepharose beads (i.e. immunoprecipitation), and subjected to SDS-PAGE and Western Blot. During SDS-PAGE, proteins are electrically separated on a polyacrylamide gel according to size and charge, transferred to nitrocellulose membrane and incubated with antibodies (Western Blot; WB). The advantages of using immunoprecipitation instead of whole cell lysate is that i) the number of “bands” on the gel is limited giving a “purer” blot, ii) due to amplification of the proteins larger quantities can be loaded on the gel, iii) associated proteins can be detected after stripping and re-probing with additional antibodies. In this study, we have used anti-Pyk2 antibodies together with phosphotyrosine antibodies, to immunoprecipitate Pyk2 and screen for phosphorylated Pyk2 proteins. Phagocytosis and production of reactive oxygen species Different approaches can be used to quantify phagocytosis. The amount of fluorescent conjugated particles, associated to the cells can be quantified by flow cytometry. Using light microscopy, phagocytosis can be estimated directly. Phagocytosis, especially FcR-mediated, has been shown to be a good model system for studying adhesion signalling (reviewed in (183)), and was therefore used as a biological read-out to evaluate the involvement of Cdc42 in this study. The effect of GTPases on phagocytosis and phagocytosis-mediated signalling was evaluated by light and fluorescence microscopy. Statistical analysis Student´s t-test was used to calculate the significance of results displaying a Gaussian distribution. When data lacked Gaussian distribution, a non parametric test was chosen i.e. Mann Whitney test when comparing two groups, or Kruskal-Wallis one-way analysis of variance by ranks together with Dunn’s post test. All the statistics were calculated using 42 GraphPad InStat version 3.0.1 (www.graphpad.com).* represents p <0.05, ** represents p<0.01, and *** p< 0.001. 43 RESULTS The effect of pro- and anti-inflammatory chemoattractants on the activation state of the β2 integrins The activation state of β2 integrins on neutrophils from healthy donors, mediated by pro-inflammatory chemoattractants One aim of this thesis was to elucidate the effect of pro-inflammatory substances e.g. fMLP, LTB4, and IL-8 on the activation state of β2 integrins in human neutrophils. Upon activation, the connection between integrin receptors and the cytoskeleton is momentarily broken (60), allowing lateral movement of the receptors in the plasma membrane (184). β2 integrins cluster on the membrane and form focal complexes to which structural and signalling molecules are recruited, thereby enhancing the avidity of the receptor for its ligand, and the signalling capacity. Analysis of the mobility and clustering of integrin receptors on the plasma membrane showed that the chemoattractant LTB4 induced an increase in β2 B integrin mobility and the formation of both small and large clusters (Paper I, and Fig. 14). The chemoattractant fMLP on the other hand, was less potent compared to LTB4 in mediating lateral mobility of the integrins and induced formation of predominantly small β2 integrinclusters on neutrophil-like HL60 cells (Paper I, and summarized in Fig.14). In order to determine the affinity status of β2 integrins, two α-integrin antibodies were used i) an antibody recognizing a high affinity epitope on the α-subunit of both CD11a and CD11b integrins (MAb24) (172), and ii) antibodies recognizing the ligand binding domain (I-domain) on CD11b integrins (CBRM 1/5). It has been disputed whether the results obtained by these antibodies correlate with ligand binding or not (185). Therefore, our results were confirmed by measuring the binding of soluble ICAM (s-ICAM), a natural ligand to β2 integrins. The binding studies confirmed the results on β2 integrin affinity showing that fMLP, but not LTB4, induced an affinity change of the β2 integrins (Paper I). Lately, arachidonic acid, the pre-cursor of both pro-and anti- inflammatory eicosanoids, has emerged as a mediator of inflammatory responses. In HL60 cells, arachidonic acid induced a small 44 release of [3H]AA and mediated an increase in β2 integrin affinity (Paper III). Arachidonic acid also induced an increase in the avidity of β2 integrins in differentiated HL60 cells (Fig. 13, unpublished results), supporting a role of arachidonic acid as mediator of the activation of β2 integrins. A 250 AA 20uM AA 100uM NKLI16 MFI (% of control) 225 200 175 150 125 100 75 50 0 5 10 Time (min) Figure 13. The effect of arachidonic acid on the β2 integrin avidity in differentiated HL60 cells. Differentiated HL60 cells were stimulated with 20 μM or 100 μM of arachidonic acid (AA) for various time-points. The cells were fixed in PFA for 15 minutes and incubated with NKLI16 antibodies recognizing clustered integrins. Increase in integrin avidity was evaluated by flow cytometry. Data are expressed as % of control from one experiment. The effect of anti-inflammatory substances on the activation state of β2 integrins The anti-inflammatory, exogenous lipoxin analogues (LXa) were used as a tool for elucidating the signalling pathways that regulate the β2 integrin activation and to investigate the effect of anti-inflammatory substances per se. LXa inhibited the formation of small fMLPmediated clusters by half, but had no effect on the LTB4-mediated formation of small clusters (Paper I). The large, LTB4-mediated β2 integrin clusters were sensitive to LXa-treatment. B LXa had no effect on the fMLP-induced, β2 integrin affinity (Paper I and summarized in Fig. 14). In conclusion, LXa seems to regulate the activity of β2 integrins mainly by affecting the avidity of the adhesion receptors. 45 Lateral mobility Clustring Affinity + ligand binding ICAM-1 β2 integrins Small clusters Large clusters no effect fMLP + ++ (+ LXa) (-) (- -) +++ LTB4 +++ ++ + + (+ LXa) (- -) (-) (-) (no effect) (no effect) Figure 14. The effect of fMLP and LTB4, on the activation state of β2 integrins on neutrophils. A schematic illustration of the results presented in Paper I. The fMLP induced increase of integrin affinity and ligand binding is insensitive to LXa treatment. LTB4 on the other hand, has only a weak effect on β2 integrin affinity, but a strong effect on both the mobility of β2 integrins, as well as clustering. LXa inhibits the LTB4-mediated mobility and clustering of β2 integrins but has no effect on the LTB4mediated β2 integrin affinity. + represents weak positive effect; ++ intermediary effect; and +++ strong positive effect. The effect of LXa on the fMLP- and LTB4-mediated activation of β2 integrins is given in parenthesis. – represents weak inhibition, and – – represents a strong inhibition. B The activation state of β2 integrins on neutrophils from patients with stable CAD After analyzing β2 integrin mediated signalling in under normal conditions, the signalling capacity of neutrophils from patients suffering from stable coronary artery disease (CAD) was investigated. Circulation of leukocytes and extravasation to the tissues is one part of the normal inflammatory response. Abnormal accumulation of leukocytes in target tissues is connected to a variety of diseases such as: rheumatoid arthritis, multiple sclerosis and atherosclerosis (186). The activation state of β2 integrins was investigated by quantifying the number of β2 integrins on the plasma membrane as well as the affinity of the β2 integrin receptors on neutrophils from CAD patients compared to age and gender matched healthy donor subjects. The medication administered to all CAD patients consists of a low dose 46 aspirin combined with statins. Statins affect a number of signalling molecules important for adhesion (187), and aspirin induces the formation of endogenous, anti-inflammatory substances, i.e. 15-epi lipoxins, earlier found to inhibit the avidity state of the β2 integrins (Paper I). Our study showed that there was no difference between patients and control subjects, in neither the expression-, or in the affinity of β2 integrins during basal conditions (Paper V). The lack of a primed status of neutrophils shows that the therapy of today is sufficient in maintaining the neutrophils in a non-reactive state, thereby limiting progress of the disease. The effect of pro- and anti- inflammatory substances on the signalling capacity of β2 integrins Signalling capacity, as measured by the release of arachidonic acid After investigating the activation state of β2 integrins on neutrophils from healthy donors and CAD patients, the aim was to look more closely at the signalling capacity of the β2 integrin receptors. Arachidonic acid (AA) is a poly-unsaturated lipid incorporated in cell membranes, which is released upon stimulation and metabolized into eicosanoids. In other words, arachidonic acid is a precursor for both pro-inflammatory (e.g. LTB4) and anti-inflammatory (lipoxins) eicosanoids. Starting this investigation, AA had been found to be released in HeLa cells adherent to collagen (188). In macrophages on the other hand, CR3-mediated (β2 integrinmediated) phagocytosis did not activate arachidonate release (189). We found that in HL60 cells kept in suspension, ligation of β2 integrins by pansorbins induced a release of [3H]AA (Paper III, and summarized in Fig. 15A). fMLP by itself, induced a substantial release of [3H]AA, and enhanced the release mediated by β2 integrin-ligation probably due to inside-out signalling (Paper III, and summarized in Fig. 15A). Depletion of calcium affected the AA release, probably due to the fact that calcium is necessary for the activation of PLA2 and for the activation of β2 integrins per se (Paper III). The intermediary chemoattractant LTB4 on the other hand, did not induce any release of [3H]AA in differentiated HL60 cells (Fig. 15B, unpublished results, and summarized 15A). 47 A 450 β2 pansorbin B [3H]AA release (% of control) 400 fMLP LTB4 + AA 350 300 250 200 150 100 50 Increase of: β2 integrin affinity and avidity, amount of F-actin, and fillipodia formation 0 fMLP LTB4 Figure 15. The effect of fMLP and LTB4 on the release of arachidonic acid in differentiated HL60 cells. A) A schematic illustration on the effect of fMLP and LTB4 on the β2 integrin-mediated release of arachidonic acid in HL60 cells. In contrast to LTB4, both fMLP and β2 integrin-pansorbins induce the release of [3H]AA. Preincubation of fMLP potentiates the fMLP-mediated release of AA. Data are presented in Paper III. B) The release of [3H]AA in differentiated HL60 cells. HL60 cells were incubated with [3H]AA for 18-24 hours. The cells were washed and pre-incubated for 1 minute prior to stimulation with fMLP (100 nM) or LTB4 (100 nM) for 5 minutes. The stimulation was stopped by centrifugation, and the radioactivity of supernatant was measured in a β-scintillation counter. For more details see Materials and methods section in Paper III. Data shown are expressed as mean ± SEM from 4 separate experiments, run in duplicates. Arachidonic acid, released via active β2 integrins and by fMLP, could become further metabolized into eicosanoids, or affect biological processes per se. Plasma levels of free arachidonic acid vary between 6-50 μM (190), but can under pathological conditions increase to both 100 μM (malaria) and 500 μM (brain ischemia) (191). A low concentration of arachidonic acid (20 μM) had no effect on cellular morphology and F-actin-content in HL60 cells (Fig. 16 and 17, unpublished results). Cells exposed to 100 μM of arachidonic acid on the other hand, displayed a more round morphology with extensive fillipodia formation (Fig. 16, unpublished results), and increased level of F-actin (Fig. 17, unpublished results). 48 A B AA 20μM AA 100μM Figure 16. The effect of arachidonic acid on the cellular morphology of HL60 cells. Differentiated HL60 cells were pre-incubated with arachidonic acid (AA) prior to plating for 15 minutes on glass slides pre-coated with IgG-opsonized yeast. Incubation was stopped by addition of ice-cold PFA, followed by permeabilization and staining of Factin in PBS supplemented with lysophosphatidylcholine and Alexa 594-conjugated phalloidin. Panels A) show HL60 cells during spreading and chemotaxis, and B) during phagocytosis. The data shown are representative of two independent experiments. B F-actin MFI (% of control) 300 250 200 150 100 AA fMLP Figure 17. The effect of arachidonic acid on the amount of F-actin in differentiated HL60 cells. Differentiated HL60 cells were stimulated with 100 μM arachidonic acid (AA) or 100 nM fMLP and fixed in PFA for 15 minutes. F-actin was labelled with FITC-conjugated phalloidin and evaluated by flow cytometry. Data are expressed as median values from two independent experiments. 49 The signalling capacity of β2 integrins, measured by production of reactive oxygen species The signalling capacity of β2 integrins was determined by analyzing the effect of the proinflammatory chemoattractants LTB4 and IL-8, on the C3bi- (i.e. β2 integrin) mediated ROSproduction in neutrophils from healthy donor subjects. Compared to the β2 integrin-mediated intracellular release, the chemoattractants mainly induced a extracellular production of ROS (Paper V, and summarized in Fig. 18A). It has been proposed that the progress of disease is due to a primed state of neutrophils. However, the signalling capacity of neutrophils from CAD patient was decreased compared to healthy donors, i.e. the neutrophils from CAD patients were less prone to produce ROS when challenged with C3bi-opsonized yeast or PMA (Paper V, and summarized in Fig. 18B). We hypothesize that the impaired response to C3bi-opsonized yeast in CAD-patients could result from decreased adhesion brought about by a decreased β2 integrin avidity due to the antiinflammatory medication administered to CAD patients. 50 Aspirin LTB4 O2- LTB4 IL-8 O2- O2 O2 O2- Statin IL-8 O2- O2 O2 O2- A O2 O2- O2 B Figure 18. A schematic illustration over the production of reactive oxygen species in human neutrophils. A) The chemoattractants; LTB4 and IL-8, mainly induce extracellular production of reactive oxygen species (ROS) in neutrophils from healthy donor subjects. The production mediated by β2 integrins on the other hand, is predominantly intracellular. B) The β2 integrin-mediated production of ROS is impaired in human neutrophils from CAD patients, which are given statins and aspirin. For more details see paper V. The effect of pro- and anti-inflammatory substances on the signal transduction mediated by β2 integrins After investigating the mobility, clustering, and affinity of β2 integrins, the focus was turned to their signal transduction. This process involves β2 integrin- mediated scaffolding of cytoskeletal proteins and signalling molecules, and utilizes the cytoskeleton as a matrix for the interactions. One of the signalling events activated by ligation of β2 integrins is phosphorylation of proteins mediated by protein tyrosine kinases. When this investigation was initiated in 1998, FAK had been detected in cell lysates of human neutrophils, but was not activated by adhesion in these cells. Another member of the family of non-receptor protein tyrosine kinases, Pyk2, was expressed in hematopoietic cells (104). The aim was therefore to investigate the role of Pyk2 in β2 integrin-mediated signalling in HL60 cells. The strong 51 tyrosine phosphorylation of Pyk2 induced by fMLP and ligation of β2 integrins in cells kept in suspension was mediated by Src and PKC (Paper II, and summarized in Fig 19) (35, 103). The chemoattractant LTB4 on the other hand, did not induce phosphorylation of Pyk2 at any B given time or concentration. Adhesion to fibrinogen also induced phosphorylation of Pyk2 in HL60 cells, although to a lesser extent compared to β2 pansorbins (Paper II). This can be explained by the ability of the pansorbins to cross-link integrin receptors in the plasma membrane, thereby mimicking clustering/scaffolding of the integrins. Moreover, preincubation with fMLP or LTB4 prior to adhesion, increased the integrin-mediated Pyk2 phosphorylation, most probably due to pre-activation of β2 integrin receptors by inside-out signalling (Paper II, and summarized in Fig. 19). LXa inhibited fMLP-induced phosphorylation of Pyk2 in cells kept in suspension, but did not affect the β2 integrin mediated Pyk2 phosphorylation in cells adherent to fibrinogen (Paper II). Our results concerning the effect of fMLP and LTB4 on the lateral mobility, clustering, affinity and signalling capacity of β2 integrins (summarized in Fig. 14), support the idea that different chemoattractants activate distinct signalling pathways during β2 integrin mediated signalling (128, 129). Lipoxins emerge as potential anti-inflammatory drugs, and Pyk2 may be a suitable target for the action of these drugs. 52 Inhibition Activation β2 pansorbin fMLP LTB4 ? LXa Pyk2 P Figure 19. Schematic illustration about the effect of chemotactic stimuli on β2 integrin-mediated adhesion in neutrophils. The effect of fMLP and LTB4 on the phosphorylation of Pyk2 in HL60 cells in suspension. Ligation of β2 integrins by pansorbins induces a phosphorylation of Pyk2 in differentiated HL60 cells. The chemoattractant fMLP phosphorylates Pyk2. Due to the strong activation of Pyk2 by β2pansorbins, it is impossible to evaluate the effect of fMLP on the pansorbin-mediated phosphorylation of Pyk2. Pre-incubation with the anti-inflammatory lipoxin analogues (LXa) inhibits fMLP-mediated activation of Pyk2. Data are presented in detail in paper III. 53 Since arachidonic acid was found to mediate the activation status of β2 integrins (Paper III), the effect of arachidonic acid on the phosphorylation of Pyk2 was investigated. Stimulation with arachidonic acid (100 μM) had no effect on the phosphorylation of Pyk2 (Fig. 20, unpublished results). IP:Pyk2 - + - - AA + fMLP WB:4G10 WB:Pyk2 Figure 20. The effect of arachidonic acid on the phosphorylation of Pyk2 in differentiated HL60 cells. Serum starved HL60 cells were stimulated with arachidonic acid (AA; 100 μM) or fMLP (100 nM) for 2.5 minutes and lysed in ice-cold lysis buffer. The cells were centrifuged at 12000 x g for 10 minutes, and Pyk2 in the supernatant was immunoprecipitated (IP) by anti-Pyk2 antibodies (#600) together with protein A sepharose. The samples were subjected to SDS-PAGE, and western blot (WB). After blocking, the membranes were incubated with phosphotyrosine antibodies (4G10). In order to ensure proper loading, membranes were stripped and incubated with anti-Pyk2 antibodies. These results are supported by our finding that the AA-metabolite, LTB4 does to induce B phosphorylation of Pyk2 (Paper II), in likeness of its precursor AA. Additional experiments are however needed to understand the effect of arachidonic acid on the activation of β2 integrin mediated signalling. Additional methods to study proteins important for the regulation of β2 integrins In order to claim a protein to be of importance for a cellular process, the effect of inhibition of the protein must be investigated. Pyk2 was earlier proposed to be a protein involved in the signalling mediated by β2 integrins. No specific inhibitors of Pyk2 were commercially available when this study was initiated, but the effect of tyrosine kinase inhibitors suggested involvement of Pyk2 in β2 integrin-mediated signalling (Paper II). A way to introduce constitutively active and dominant negative, recombinant forms of Pyk2 was therefore 54 needed. Transfection of neutrophils/HL60 cells by; Lipofectamine, DEAE-dextran, electroporation, and retro-viral approach was however unsuccessful, hence other transfection methods needed to be established. TAT-protein transduction The TAT-transduction method which utilizes short sequence of HIV-Tat protein expressed as a fusion protein was exploited. Due to the small size of Cdc42 (approx. 25kDa), it was considered as a suitable protein for optimizing the transduction method in neutrophils and differentiated HL60 cells (Paper IV). Moreover, the fact that Cdc42 is activated by both β2integrin ligation and stimulation with both fMLP and LTB4 in human neutrophils (data not shown), and that G-proteins are involved in the activation of Pyk2, made Cdc42 highly interesting to investigate. Enzymatic degradation of TAT-Cdc42 fusion proteins in human neutrophils forced us to focus on differentiated HL60 cells. After optimizing the procedure, differentiated HL60 were successfully transduced with TAT-Cdc42 (Paper IV). As a biological read-out, the effect of constitutively active- (V12) and dominant negative(N17) forms of TAT-Cdc42 on IgG-mediated phagocytosis was analyzed. Staining of F-actin by phalloidin, revealed that cells transduced with constitutively active TAT-Cdc42 displayed a pronounced accumulation of F-actin, both at the leading edge of the cell and around the phagosome (Paper IV, and in Fig. 23), which was also confirmed by scanning electron microscopy experiments (Paper IV). TAT-N17Cdc42 on the other hand, had no effect on the F-actin content. None of the TAT-proteins affected phagocytosis of IgG-opsonized yeast per se (Paper IV), despite the fact that TAT-N17Cdc42 inhibited chemotaxis to a small extent (20% reduction, Fig. 21, unpublished results). 55 non transduced TAT-V12Cdc42 TAT-N17Cdc42 140 120 Migration 100 ** * 80 A 60 a 40 b 20 B 0 a b a/b Figure 21. fMLP-induced chemotaxis of TAT-Cdc42 transduced HL60 cells. Differentiated HL60 cells, non-transduced were transduced with constitutively active (V12) and dominant negative (N17) TAT-Cdc42 proteins for 30 minutes. Three wells were cut out in an agarose gel casted in a petri-dish. HL60 cells were applied to the mid-well, fMLP in one well (A) and buffer in the other well (B). Cells were allowed to migrate towards the chemoattractant for one hour. After fixation with PFA, the cells were stained with Giemsa, and migration was evaluated in a light microscope, using an ocular containing a ruler. Chemotaxis was evaluated as migration index (a/b), where a represents the migration against a chemotactic gradient and b the spontaneous migration of cells. Data are shown as mean ± SEM for migration (% of non transduced cells) of three separate experiments run in triplicates. The presence of an F-actin ring around the phagosome seemed to correlate with the lack of CD63 positive granules (Paper IV) and was therefore subjected to further investigation. To analyze translocation of CD63 positive granules, cells were loaded with Lysotracker® and the movement of granules was recorded (Paper IV). Using quantitative image analysis, the following scenario unravelled. In non-transduced cells, the ingested particle is located in a phagosome surrounded by a transient ring of F-actin. Constitutively active Cdc42 induced the formation of a thick F-actin ring affecting phago-lysosome maturation. The F-actin has to be dissolved to allow fusion of granules with the phagosome. Cdc42 is also involved in the actual translocation of granules to the phagosome, since dominantly negative Cdc42 resulted in non-aggregated granules, randomly dispersed in the cell (Paper IV, and summarized in Fig. 22). 56 ∗ Control ∗ ∗ TAT-V12Cdc42 TAT-N17Cdc42 F-actin CD63 positive granules Figure 22. A schematic illustration on the effect of active/inactive Cdc42. In control (non-transduced) cells the F-actin surrounding the phagosome is depolymerized during phago-lysosome formation, allowing fusion of granules with the phagosomal membrane. Transduction of cells with constitutively active (V12) form of Cdc42 induces an accumulation of F-actin around the phagosome, impeding granule-phagosome fusion. In cells transduced with dominant negative Cdc42 (N17), the appearance of the F-actin ring around the phagosome resembles control cells, but translocation of granules to the phagosome is impaired. The results summarized in this figure are presented in detail in paper IV. Transduction of HL60 cells with TAT-Pyk2 After optimizing the transduction method by using TAT-Cdc42, we were interested in transducing the cells with TAT-Pyk2. By then, TAT-Pyk2 had successfully been transduced into neutrophils (192). Differentiated HL60 cells were transduced with C-terminal part of Pyk2, earlier shown to inhibit ROS production in neutrophils (192). It proved difficult to transduce TAT-Pyk2 proteins into differentiated HL60 cells; probably due to the larger size of TAT-Pyk2-fusion proteins compared TAT-Cdc42 proteins, and further optimization is necessary. Nevertheless, protein transduction of HL60 cells with CT-Pyk2 had no effect on the fMLP-mediated induction of β2 integrin affinity, nor on the β2- and fMLP-mediated release of [3H]AA (data not shown); indicating that Pyk2 is not involved in these processes. 57 SUMMARY Inhibition Activation Lxa, Aspirin + LTB4 -R fMLP-R Pyk2 P ROS ROS AA F-actin IL-8-R ”Active” β2 integrins Lxa, Aspirin LXA4 -R Figure 23. The regulatory effect of pro- and anti- inflammatory mediators on the β2 integrin-induced signalling in neutrophils. Prior to adhesion, integrin receptors are activated by chemokines and chemotactic factors. The pro-inflammatory chemoattractants fMLP and LTB4, mediate an increase in the lateral mobility and clustering of β2 integrins. The affinity of β2 integrins, on the other hand, is mainly increased by fMLP, and is not sensitive to treatment with the anti-inflammatory lipoxin analogue (LXa). Also the β2 integrin-mediated tyrosine phosphorylation of Pyk2 is insensitive to LXa treatment. Besides inducing phosphorylation of Pyk2, ligation of fMLPand β2 integrin-receptors (R) releases arachidonic acid (AA). Moreover, pre-incubation of fMLP augments the β2-mediated release of AA. AA per se induces an increase in β2 integrin affinity and avidity and increases the amount of F-actin. Pre-incubation with the anti-inflammatory lipoxin analogues (LXa) or treatment with aspirin, inhibits fMLPmediated activation of Pyk2, and the β2-mediated release of ROS. The data summarized in this figure are presented in detail in Papers I-V, and as unpublished observations. 58 CONCLUDING REMARKS AND FUTURE PERSPECTIVES When investigating the regulatory effect of pro- and anti-inflammatory substances on the β2 integrin-mediated signalling in neutrophils, more questions were raised concerning: i) The activation state of the β2 integrins (i.e. affinity, avidity). - Does Pyk2 modulate the β2 integrin affinity/avidity? - Does Cdc42 mediate in the activation of β2 integrins? - What is the roll of small GTPases (e.g. Rac, Cdc42, and Rap1) in the regulation of β2 integrin affinity? ii) The signalling capacity of β2 integrins (i.e. AA release and ROS production). More specifically, the questions would be: iii) - Does the anti-inflammatory lipoxin (LXa) affect the release of AA? - Does IL-8 induce release of AA? - How is the AA-release mediated in CAD patients? - Does AA per se induce the release of ROS? - Is the β2 integrin mediated release of ROS dependent of Pyk2 activation? The signal transduction mediated by β2 integrins (i.e. Pyk2 phosphorylation). The more specific questions would be: - Which tyrosine phosphorylation sites on Pyk2 are activated upon stimulation with the pro-inflammatory chemoattractants LTB4, and fMLP? - What is the effect of LXa on these phosphorylation sites? - Does Pyk2 associate with β2 integrins prior or after stimulation with pro- and anti-inflammatory substances? Does α-actinin/talin associate with Pyk2 in β2 integrin-stimulated HL60 cells? In other words, is Pyk2 a scaffolding protein during β2 integrin-mediated signalling? - What effect do dominant negative- and constitutively active forms of Cdc42 have on the activation of Pyk2? The questions are never-ending… So, to my fellow scientists out there: I turn over the baton to you! 59 ACKNOWLEDGEMENTS Many people have contributed in the making of this thesis, and I am grateful for all the support I received along the way! Detta är ett av de få tillfällen man har här i livet att verkligen tacka alla som har betytt något. Så nu får ni stå ut med att det blir några sidor. Jag har ju haft turen att träffa så många trevliga människor och lära känna så många nya vänner genom åren! Jag vill speciellt tacka: Min handledare, Eva Särndahl. Tack för allt stöd och all uppmuntran genom åren! Tack för att du efter alla år (11) ser till att upprätthålla mitt intresse för forskning. Det är så mycket man kan lära av dig: att vara en bra pedagog, att framgångsrikt skriva en forskningsplan och söka anslag, och att inte ge upp i första taget! Jag har haft så kul när vi har rest tillsammans, trots förlorat bagage och alla konstiga åkommor… Tack för att du delat med dig av ditt liv och din familj, det har varit roligt att få se dina barn växa upp. För att du alltid bryr dig och alltid ställer upp (ibland på bekostnad av din familj…tack familjen!). Mest av allt vill jag tacka dig för att du har ”släppt mig lös” på lab och att du (nästan) aldrig säger nej till mina vilda idéer! Du har under dessa år inte bara varit min handledare utan också blivit en väldigt god vän...och vad mer kan man önska? Olle Stendahl, min mentor och på den sista tiden också min biträdande-handledare. Tack för att du engagerar dig, delar med dig av din stora kunskap, kommer med så bra synpunkter och tack för att du alltid tar dig tid! Tack för att du är med oss i med och motgång... och för att du blev nästan tusen gånger gladare än jag när manuset gick in till slut… Pia Druid: Den bästa som finns! Tack för allt genom åren, inte bara all laborationsmässig hjälp (som har varit super…”utan dig är vi intet”) utan också för allt ”skitsnack” och alla härliga skratt. Tack för att du har brytt dig om och för att du ringt mig varje vecka under mina barnlediga år! Jane Wigren: Tack för att du såg till att labbet inte blev alltför ödsligt när Eva och Pia tillfälligt ”emigrerade”. Du är alltid så trevlig och hjälpsam och din korrekturläsning höjer engelskan till nya nivåer. Vi syns vid kanalen i sommar (jag fika…du löpa…!) Liselotte Ydrenius: Vad vi har haft kul genom åren! Hotten-Totten, tack för att din humor (om än konstigare än min) och dina humörsvängningar. Det var min stora uppgift att retas med dig tills du skrattade… jag lyckades för det mesta. Jag saknar det hasande ljudet av dina tofflor! Martin Tinnerfelt Winberg, min ”lillebror” på labbet. Tack för allt skoj, för att du har stått ut med alla ”tjuvnyp” och för att du gillar att kramas! Sailesh Surapureddi, my sweetheart! Thanks for all the fun in the lab, for all the great meals and for introducing me to “Pidgin English”. Maria Lerm, för att du alltid hjälper till och alltid stöttar. Alla våra studenter genom åren: Ida, Iida, Anna, Martin, Annelie, Calle, Malin, Pernilla, Emma, Hanna och alla andra…tack för att ni bidragit till att höja stämningen på lab. Några av mina rumskamrater genom åren: Jesper Svartz, Kristina Loinder och Tobias Strid. 60 Tänk vad mycket man får reda på i doktorandrummet! Tack för att jag fick störa er hela tiden. Även om vetenskap kan vara kul att diskutera, så finns det ju andra saker här i livet som jag hellre pratar om…som ni har märkt. Jesper, som också har varit NIR-doktorand, har jag haft turen att få äta många lyxiga hotellfrukostar med i Lund. Vi har haft en massa skoj på alla kurser och konferenser! Det finns bara en som du! På gränsen till för mycket…men sååå rolig! Mina andra rumskamrater Johan Paulsson, Sofia Nyström och nyligen Sebastian Schultz. Johan, ”the rising star over there”, du är inte bara trevlig, och smart…du är ju snygg också…jag kommer att sjunga om dina biceps varje dag när du har åkt. Sofia, en av mina ”medbrottslingar” på Cellbiologen sedan länge. Skönt att ha någon som vad jag menar när jag pratar om ”gamla tider”. Jag kommer att sakna dina monologer och att hitta dina nycklar och plånböcker överallt…Sebastian, tack för att du såg till att jag fick nya ”bevingade” kompisar på labbet. ”Strålforskningsgruppen” och ”Nyström gruppen”, nya som gamla: Unn Örtegren Kugelberg, Karin Stenkula, Nabila Aboulaich, Anita Öst, Siri Fagerholm, Elisabeth Hallin, Hans Thorn, Margareta Karlsson, Santiago Parpal, Anna Danielsson, Lilian Sauma, Nicklas Franck, Fredrik Nyström, Johanna Gustavsson och alla nya som jag ännu inte har lärt mig efternamnet på: Åsa, Iida, Cecilia och Gunnar. Tack för allt genom åren, för alla roliga ”spex” och fester. … arbetet är inte allt! Nabila som bevisar att man kan vara supersmart och se bra ut samtidigt …och vara ödmjuk! Anita, jag önskar att jag hade åtminstone hälften av din drivkraft. Och så är du så trevlig dessutom. Framtida doktorander kan skratta sig lyckliga att få dig som handledare! Siri för att du är alldeles för snäll! Elisabeth, som verkar vara redo att ”axla min mantel”, lika frispråkig som jag (nästan), men skäller lite mer (men det kanske behövs) och jobbar desto mer. ”Hanse” som delade min skruvade humor och som jag hade så roligt med i forskarskolan …hur var det nu med kavajen? Vi syns när du kommer tillbaka! Margareta, vår egen sångfågel, tack för de här åren och hoppas att du orkar ta ton på en fest till! Santi för att du alltid avbröt dina experiment för att hjälpa andra. Johanna, tack för alla djupa diskussioner om relationer och för att du läste min avhandling. Peter Strålfors, mannen vars åsikter jag oftast inte delar (det har nog inte undgått någon?!). Tack för att du alltid har engagerat dig och brytt dig om hur det går för mig och för att du tar dig tid! Jag kommer att sakna våra ”diskussioner”...Vem ska nu säga emot dig? Gunilla Westermark, tack för alla sena diskussioner och för att du alltid delar med dig av din gourmet mat! Jana Sponarova Jano, thanks for your friendship. I’m sorry that I am so bad at Czech. Perhaps you can find someone to speak to at the party…? Mats Söderström och Sven Hammarström. Mats, tack för all hjälp genom åren…datorer har ett eget liv! Sven, tack för att du delar med dig av din stora kunskap och för att du tog dig tid att läsa både manus och delar av avhandlingen. Lärarna på Medicinsk Bilogi T3: Mats Lindahl, Tony Forslund och Margareta Lindroth. Mats och Tony, det har varit kul att få ”bestämma lite” i terminsgruppen. Hoppas att ni hittar något annat offer som vill läsa alla ”uppsatser”. Margareta, alltid så glad och så kunnig! Du är bäst!...och söt i din nya frisyr… ”Gamlingarna” på HU: Carina Hellberg, Eva Grönroos och Ranghild Löfgren och Karin Björnström. Tack Carina för att jag fick ta hand om ”jätte-bebisen” Tulle. ”Evis”, du och jag tillsammans blir nästan för mycket. 61 De övriga på Cellbiologen, Mikrobiologen, och Farmakologen: Lotta Ericsson, Anna Berg, Cecilia Trinks, Peter Påhlsson Maria Lerm, ”flödesexperten” Tony Forslund, Torbjörn Bengtsson, Maria Forsberg, Åsa Holm, Charlotte Immerstrand, Birgitta Rasmusson och alla ni andra. Anna, nu när jag kommer att ha all tid i världen så måste vi faktiskt se till att träffas! Alla mina vänner från Biomedicinska forskarskolan: Charlotte Anna, Petra, Karin, Hans, Johan, Jacob, Ylva, Marcus, och så naturligtvis Torbjörn och Lillemor! Tack för ett roligt år!...jag fick ”kexet” till slut! Mina vänner från NIR: speciellt Maria, Lisa, Veronica och Cecilia. Vi har haft så kul när vi har bott på Patienthotellet i Lund! Tack till Mark Hickery och Maria Olofsson för ett superbra jobb! All the people at the Ludwig Institute for Cancer Research in Uppsala: the “Boss” Calle Heldin, Ivan, Inga, my great friends Ninna, Jill, Sofia and Eva G. The rest of “the gang” Tobias, Olli, Johan, my room-mate Anders, Ann-Sofie, Andree, and of course cykelfixaren Ulf. Thank you for taking care of me and for all the fun during the late lab-nights. My supervisor Ivan Dikic, thank you for introducing me to the realities of science and the “importance” of being focused and dedicated… The people “over there” in Indianapolis: Fred Pavalko, Sarah Sawyer and all the rest. Fred, thank you for taking such good care of me during my stay! Your never failing enthusiasm, encouragement and kindness will not be forgotten. I had a great time! Thank you for giving me a ride to the lab every morning. Sarah, thank you for being such a good friend and for helping me spending my money at great restaurants and in book shops! All the rest of the people at the Indiana University School of Medicine who I had the fortune to meet…I miss you all! Patrik Lindblom, utan din hjälp hade vi inte kunnat få iväg några artiklar! Och tack för all super-god mat genom åren! Förutom forskning, så har man ju faktiskt andra intressen här i livet. Därför finns det en hel del människor som jag vill tacka! Unn och Fredrik Kugelberg. Tack för att ni är så goda vänner. Ni är för snälla för ert eget bästa! Tack för alla goda middagar, viner och framför allt alla icke vetenskapliga diskussioner genom åren och för allt stöd. Nu när förkylningsperioden är över så kanske jag kan få krama på Inger lite mer! Hoppas att ni slipper flytta åt oss en femte gång… Karin Stenkula och Johan Tengelin. Tack för all vänskap. Alla goda middagar (ett återkommande tema!) och alla skratt. Ihop med yrvädret Karin kan man inte annat än skratta! Karin, tack för att du har delat mitt ”livsfarliga” hästintresse genom åren… Synd att ni har flyttat till Örebro…men vem vet vi kanske flyttar efter?! Charlotte och Björn Immerstrand. Charlotte, den mest positiva människan jag någonsin träffat!...förutom din man Björn kanske. Det är alltid så trevligt att umgås med er och era barn. Vi ser fram emot att plaska i poolen i sommar också! Helena Negga. Det är sällan som man träffar någon som ger så mycket av sig själv utan att kräva något tillbaka, men du är precis en sådan människa! Tack för allt ditt stöd, för dina kloka råd och din inställning till livet. Nu kanske vi kan träffas mer! Micke, tack för din vänskap och för att du pratar träning med min man…så att jag slipper. 62 Christel Winell för allt roligt vi hade på labbet och för att jag fick vara en del av din familj under en ganska lång tid… Josefin Axelsson (numera Perman), ”biologen” som övergav mig till förmån till läkarlinjen. Det var ju så tråkigt att du slutade, men idag är jag glad att vi har en egen ”familjeläkare”. Tack för alla våra låånga telefonsamtal genom åren, för allt fikande och shoppande. Det var kul att titta på tv (läs ER) tillsammans per telefon… Hoppas att jag får träffa guldklimpen snart! ”Mahjong-gänget” : Camilla Wohlgemuth, Annika Silvervarg och Kristina Pieslinger. Tack för alla Mahjong dagar, med chips, dipp, en massa prat och lite spelande…tänk att jag inte har vunnit en hel omgång en enda gång, trots att vi har spelat i sex (?!) år! Camilla, tack för att du har varit min vän sedan den dagen jag knackade på hemma på Lövudden och ville låna böcker…Man blir så glad av att träffa dig! Alla våra trevliga grannar. Tack för att ni ser till att vi inte vill flytta ifrån Berg! Ulrika och Peter Bergman, tack för att ni hjälper oss så mycket med allt! Passar våra barn och bjuder på god mat. Jag uppskattar det! Tack Ulrika för att du utan att tveka skjutsade in mig till jobbet när jag behövde referenser och för att du släpar ut mig på promenader så att jag får ”röra på fläsket”. Karin och Magnus Seger, våra ”jobbiga” grannar tvärs över som alltid fixar på huset, i trädgården eller är ute och motionerar…suck! Karin tack för alla kaffepauser, goda kakor, middagar och allt ”skitsnack”…jag behövde det när jag skrev! Vilken tur att du håller mig uppdaterad på allt som händer i Berg! Tack för att ni inte har ”gjort er av med” våra katter ännu… Sist, men inte minst så måste jag få tacka mina nära och kära. Mina svärföräldrar Inger och Lars, tack för att ni har hjälpt oss så mycket genom åren. My family in the Czech republic. I hope to see you soon! Min familj som ibland kan likna ”the Fockers”… Min mamma Rumenka som alltid sätter sig i bilen och kommer om jag behöver det. Tack mamma för att du alltid stöttar mig i det jag vill göra. Jag hoppas att jag kan uppfostra mina barn lika bra som du har gjort! Stig, som är bra på allt! Vår egen handy-man som fick en massa barn på köpet när han gifte in sig i vår familj. Min syster Petra och Andreas, familjens ”Barbie och Ken ” (lika snygga men mycket smartare). Petra, …lika rättfram som jag, men inte riktigt lika diplomatisk…en konstnärsjäl som är bra på det mesta. Jag är så glad att du finns! Vi har haft mycket kul genom åren. Tack för alla sena nätter på msn… Puss till mosters Isac! 63 Min lillebror Daniel (inte så liten nu för tiden). En duktig musiker, designer, helt enkelt skitbra på att flyga modellflygplan…och att ragga tjejer på nätet. Jag är stolt över dig! Mina barn, Ella och Alexander. För all er villkorslösa kärlek! Min man, Greger. Att skriva avhandling med två små barn är stundtals väldigt jobbigt och då behöver man allt stöd man kan få. Greger, tack för att du har funnits vid min sida i alla dessa år. Du är den mest kärleksfulle och omtänksamme man och pappa man kan tänka sig…om än stundtals lite tankspridd. Vilken tur att jag inte gav upp fast du fattade så trögt! Tack för all din kärlek. Jag älskar dig! The research presented in this thesis was supported by the following grants: • Ph.D. student fellowship from the Network for Inflammation research (NIR) funded by the Swedish foundation for Strategic Research (SSF) • Fellowship from the Swedish Heart & Lung Foundation • Swedish Research Council • King Gustaf V Memorial Foundation • Swedish Medical Society • Medical County Council of Östergötland • Lars Hierta Foundation 64 REFERENCES 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. Worthylake, R. A., and K. Burridge. 2001. Leukocyte transendothelial migration: orchestrating the underlying molecular machinery. Curr Opin Cell Biol 13:569-577. Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314. Moissoglu, K., and M. A. Schwartz. 2006. Integrin signalling in directed cell migration. Biol Cell 98:547-555. Hemler, M. E. 1990. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 8:365-400. Hynes, R. O. 2002. Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687. Xiong, J. P., T. Stehle, B. Diefenbach, R. Zhang, R. Dunker, D. L. Scott, A. Joachimiak, S. L. Goodman, and M. A. Arnaout. 2001. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 294:339-345. Takagi, J., B. Petre, T. Walz, and T. Springer. 2002. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110:599. Nishida, N., C. Xie, M. Shimaoka, Y. Cheng, T. Walz, and T. A. Springer. 2006. Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity 25:583-594. Adair, B. D., J. P. Xiong, C. Maddock, S. L. Goodman, M. A. Arnaout, and M. Yeager. 2005. Three-dimensional EM structure of the ectodomain of integrin {alpha}V{beta}3 in a complex with fibronectin. J Cell Biol 168:1109-1118. Beglova, N., S. C. Blacklow, J. Takagi, and T. A. Springer. 2002. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol 9:282287. 12. 13. 14. 15. 16. 17. 18. 19. 65 Puklin-Faucher, E., M. Gao, K. Schulten, and V. Vogel. 2006. How the headpiece hinge angle is opened: New insights into the dynamics of integrin activation. J Cell Biol 175:349-360. Shimaoka, M., J. Takagi, and T. A. Springer. 2002. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct 31:485-516. Xiong, J. P., R. Li, M. Essafi, T. Stehle, and M. A. Arnaout. 2000. An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. J Biol Chem 275:38762-38767. Carman, C. V., and T. A. Springer. 2003. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr Opin Cell Biol 15:547-556. Oxvig, C., C. Lu, and T. A. Springer. 1999. Conformational changes in tertiary structure near the ligand binding site of an integrin I domain. Proc Natl Acad Sci U S A 96:22152220. Cabanas, C., and N. Hogg. 1993. Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte functionassociated molecule 1. Proc Natl Acad Sci U S A 90:5838-5842. Kinashi, T. 2005. Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol 5:546-559. Luo, B. H., C. V. Carman, J. Takagi, and T. A. Springer. 2005. Disrupting integrin transmembrane domain heterodimerization increases ligand binding affinity, not valency or clustering. Proc Natl Acad Sci U S A 102:3679-3684. Rothlein, R., M. L. Dustin, S. D. Marlin, and T. A. Springer. 1986. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137:1270-1274. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. Gahmberg, C. G. 1997. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr Opin Cell Biol 9:643-650. Gahmberg, C. G., M. Tolvanen, and P. Kotovuori. 1997. Leukocyte adhesion-structure and function of human leukocyte beta2-integrins and their cellular ligands. Eur J Biochem 245:215-232. Hogg, N., J. Harvey, C. Cabanas, and R. C. Landis. 1993. Control of leukocyte integrin activation. Am Rev Respir Dis 148:S55-59. Dransfield, I., C. Cabanas, A. Craig, and N. Hogg. 1992. Divalent cation regulation of the function of the leukocyte integrin LFA-1. J Cell Biol 116:219-226. van Kooyk, Y., P. Weder, K. Heije, and C. G. Figdor. 1994. Extracellular Ca2+ modulates leukocyte functionassociated antigen-1 cell surface distribution on T lymphocytes and consequently affects cell adhesion. J Cell Biol 124:1061-1070. Hughes, P. E., and M. Pfaff. 1998. Integrin affinity modulation. Trends Cell Biol 8:359-364. Pfaff, M., S. Liu, D. J. Erle, and M. H. Ginsberg. 1998. Integrin beta cytoplasmic domains differentially bind to cytoskeletal proteins. J Biol Chem 273:6104-6109. Sharma, C. P., R. M. Ezzell, and M. A. Arnaout. 1995. Direct interaction of filamin (ABP-280) with the beta 2integrin subunit CD18. J Immunol 154:3461-3470. Horwitz, A., K. Duggan, C. Buck, M. C. Beckerle, and K. Burridge. 1986. Interaction of plasma membrane fibronectin receptor with talin--a transmembrane linkage. Nature 320:531-533. Otey, C. A., F. M. Pavalko, and K. Burridge. 1990. An interaction between alpha-actinin and the beta 1 integrin subunit in vitro. J Cell Biol 111:721-729. Tang, P., C. Cao, M. Xu, and L. Zhang. 2007. Cytoskeletal protein radixin activates integrin alpha(M)beta(2) by binding to its 31. 32. 33. 34. 35. 36. 37. 38. 66 cytoplasmic tail. FEBS Lett 581:11031108. Naik, U. P., P. M. Patel, and L. V. Parise. 1997. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem 272:4651-4654. Rojiani, M. V., B. B. Finlay, V. Gray, and S. Dedhar. 1991. In vitro interaction of a polypeptide homologous to human Ro/SS-A antigen (calreticulin) with a highly conserved amino acid sequence in the cytoplasmic domain of integrin alpha subunits. Biochemistry 30:9859-9866. Schaller, M. D., C. A. Otey, J. D. Hildebrand, and J. T. Parsons. 1995. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol 130:1181-1187. Hannigan, G. E., C. Leung-Hagesteijn, L. Fitz-Gibbon, M. G. Coppolino, G. Radeva, J. Filmus, J. C. Bell, and S. Dedhar. 1996. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379:91-96. Miura, Y., Y. Tohyama, T. Hishita, A. Lala, E. De Nardin, Y. Yoshida, H. Yamamura, T. Uchiyama, and K. Tohyama. 2000. Pyk2 and Syk participate in functional activation of granulocytic HL-60 cells in a different manner. Blood 96:1733-1739. Tanaka, T., R. Yamaguchi, H. Sabe, K. Sekiguchi, and J. M. Healy. 1996. Paxillin association in vitro with integrin cytoplasmic domain peptides. FEBS Lett 399:53-58. Young, B. A., Y. Taooka, S. Liu, K. J. Askins, Y. Yokosaki, S. M. Thomas, and D. Sheppard. 2001. The cytoplasmic domain of the integrin alpha9 subunit requires the adaptor protein paxillin to inhibit cell spreading but promotes cell migration in a paxillin-independent manner. Mol Biol Cell 12:3214-3225. Kolanus, W., W. Nagel, B. Schiller, L. Zeitlmann, S. Godar, H. Stockinger, and B. Seed. 1996. Alpha L beta 2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytoplasmic regulatory molecule. Cell 86:233-242. 39. 40. 41. 42. 43. 44. 45. 46. 47. Shattil, S. J., T. O'Toole, M. Eigenthaler, V. Thon, M. Williams, B. M. Babior, and M. H. Ginsberg. 1995. Beta 3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin beta 3 subunit. J Cell Biol 131:807-816. Chang, D. D., C. Wong, H. Smith, and J. Liu. 1997. ICAP-1, a novel beta1 integrin cytoplasmic domainassociated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. J Cell Biol 138:1149-1157. Stroeken, P. J., B. Alvarez, J. Van Rheenen, Y. M. Wijnands, D. Geerts, K. Jalink, and E. Roos. 2006. Integrin cytoplasmic domain-associated protein-1 (ICAP-1) interacts with the ROCK-I kinase at the plasma membrane. J Cell Physiol 208:620628. Liliental, J., and D. D. Chang. 1998. Rack1, a receptor for activated protein kinase C, interacts with integrin beta subunit. J Biol Chem 273:2379-2383. Calderwood, D. A., Y. Fujioka, J. M. de Pereda, B. Garcia-Alvarez, T. Nakamoto, B. Margolis, C. J. McGlade, R. C. Liddington, and M. H. Ginsberg. 2003. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A 100:2272-2277. Johansson, M. W., E. Larsson, B. Luning, E. B. Pasquale, and E. Ruoslahti. 1994. Altered localization and cytoplasmic domain-binding properties of tyrosine-phosphorylated beta 1 integrin. J Cell Biol 126:12991309. Vuori, K., and E. Ruoslahti. 1994. Association of insulin receptor substrate-1 with integrins. Science 266:1576-1578. Vossmeyer, D., W. Hofmann, K. Loster, W. Reutter, and K. Danker. 2002. Phospholipase Cgamma binds alpha1beta1 integrin and modulates alpha1beta1 integrin-specific adhesion. J Biol Chem 277:4636-4643. Han, D. C., L. G. Rodriguez, and J. L. Guan. 2001. Identification of a novel 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 67 interaction between integrin beta1 and 14-3-3beta. Oncogene 20:346-357. Wang, W., and T. Kirsch. 2006. Annexin V/beta5 integrin interactions regulate apoptosis of growth plate chondrocytes. J Biol Chem 281:3084830856. Hogg, N., and P. A. Bates. 2000. Genetic analysis of integrin function in man: LAD-1 and other syndromes. Matrix Biol 19:211-222. Kuijpers, T. W., R. A. Van Lier, D. Hamann, M. de Boer, L. Y. Thung, R. S. Weening, A. J. Verhoeven, and D. Roos. 1997. Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. J Clin Invest 100:1725-1733. McDowall, A., D. Inwald, B. Leitinger, A. Jones, R. Liesner, N. Klein, and N. Hogg. 2003. A novel form of integrin dysfunction involving beta1, beta2, and beta3 integrins. J Clin Invest 111:51-60. Wiesner, S., K. R. Legate, and R. Fassler. 2005. Integrin-actin interactions. Cell Mol Life Sci 62:1081-1099. Zamir, E., M. Katz, Y. Posen, N. Erez, K. M. Yamada, B. Z. Katz, S. Lin, D. C. Lin, A. Bershadsky, Z. Kam, and B. Geiger. 2000. Dynamics and segregation of cell-matrix adhesions in cultured fibroblasts. Nat Cell Biol 2:191-196. Linder, S. 2007. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol 17:107-117. Linder, S., and P. Kopp. 2005. Podosomes at a glance. J Cell Sci 118:2079-2082. Linder, S., and M. Aepfelbacher. 2003. Podosomes: adhesion hot-spots of invasive cells. Trends Cell Biol 13:376-385. Nayal, A., D. J. Webb, and A. F. Horwitz. 2004. Talin: an emerging focal point of adhesion dynamics. Curr Opin Cell Biol 16:94-98. Lim, J., A. Wiedemann, G. Tzircotis, S. J. Monkley, D. R. Critchley, and E. Caron. 2007. An essential role for talin during alpha(M)beta(2)-mediated 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. phagocytosis. Mol Biol Cell 18:976985. Monkley, S. J., C. A. Pritchard, and D. R. Critchley. 2001. Analysis of the mammalian talin2 gene TLN2. Biochem Biophys Res Commun 286:880-885. Sampath, R., P. J. Gallagher, and F. M. Pavalko. 1998. Cytoskeletal interactions with the leukocyte integrin beta2 cytoplasmic tail. Activationdependent regulation of associations with talin and alpha-actinin. J Biol Chem 273:33588-33594. Zaidel-Bar, R., C. Ballestrem, Z. Kam, and B. Geiger. 2003. Early molecular events in the assembly of matrix adhesions at the leading edge of migrating cells. J Cell Sci 116:46054613. Akasaki, T., H. Koga, and H. Sumimoto. 1999. Phosphoinositide 3kinase-dependent and -independent activation of the small GTPase Rac2 in human neutrophils. J Biol Chem 274:18055-18059. Alblas, J., L. Ulfman, P. Hordijk, and L. Koenderman. 2001. Activation of Rhoa and ROCK are essential for detachment of migrating leukocytes. Mol Biol Cell 12:2137-2145. Benard, V., B. P. Bohl, and G. M. Bokoch. 1999. Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem 274:13198-13204. Geijsen, N., S. van Delft, J. A. Raaijmakers, J. W. Lammers, J. G. Collard, L. Koenderman, and P. J. Coffer. 1999. Regulation of p21rac activation in human neutrophils. Blood 94:1121-1130. Abo, A., M. R. Webb, A. Grogan, and A. W. Segal. 1994. Activation of NADPH oxidase involves the dissociation of p21rac from its inhibitory GDP/GTP exchange protein (rhoGDI) followed by its translocation to the plasma membrane. Biochem J 298 Pt 3:585-591. Takai, Y., T. Sasaki, and T. Matozaki. 2001. Small GTP-binding proteins. Physiol Rev 81:153-208. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 68 Van Haastert, P. J., and P. N. Devreotes. 2004. Chemotaxis: signalling the way forward. Nat Rev Mol Cell Biol 5:626-634. Srinivasan, S., F. Wang, S. Glavas, A. Ott, F. Hofmann, K. Aktories, D. Kalman, and H. R. Bourne. 2003. Rac and Cdc42 play distinct roles in regulating PI(3,4,5)P3 and polarity during neutrophil chemotaxis. J Cell Biol 160:375-385. Del Pozo, M. A., W. B. Kiosses, N. B. Alderson, N. Meller, K. M. Hahn, and M. A. Schwartz. 2002. Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI. Nat Cell Biol 4:232-239. Forsberg, M., P. Druid, L. Zheng, O. Stendahl, and E. Sarndahl. 2003. Activation of Rac2 and Cdc42 on Fc and complement receptor ligation in human neutrophils. J Leukoc Biol 74:611-619. Worthylake, R. A., S. Lemoine, J. M. Watson, and K. Burridge. 2001. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 154:147-160. Niggli, V. 1999. Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett 445:6972. Cherry, L. K., X. Li, P. Schwab, B. Lim, and L. B. Klickstein. 2004. RhoH is required to maintain the integrin LFA-1 in a nonadhesive state on lymphocytes. Nat Immunol 5:961-967. Michaely, P. A., C. Mineo, Y. S. Ying, and R. G. Anderson. 1999. Polarized distribution of endogenous Rac1 and RhoA at the cell surface. J Biol Chem 274:21430-21436. Kumanogoh, H., S. Miyata, Y. Sokawa, and S. Maekawa. 2001. Biochemical and morphological analysis on the localization of Rac1 in neurons. Neurosci Res 39:189-196. Del Pozo, M. A. 2004. Integrin signaling and lipid rafts. Cell Cycle 3:725-728. del Pozo, M. A., N. B. Alderson, W. B. Kiosses, H. H. Chiang, R. G. Anderson, and M. A. Schwartz. 2004. Integrins regulate Rac targeting by 79. 80. 81. 82. 83. 84. 85. 86. internalization of membrane domains. Science 303:839-842. Bos, J. L., K. de Bruyn, J. Enserink, B. Kuiperij, S. Rangarajan, H. Rehmann, J. Riedl, J. de Rooij, F. van Mansfeld, and F. Zwartkruis. 2003. The role of Rap1 in integrin-mediated cell adhesion. Biochem Soc Trans 31:8386. Katagiri, K., M. Hattori, N. Minato, S. Irie, K. Takatsu, and T. Kinashi. 2000. Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. Mol Cell Biol 20:1956-1969. Han, J., C. J. Lim, N. Watanabe, A. Soriani, B. Ratnikov, D. A. Calderwood, W. Puzon-McLaughlin, E. M. Lafuente, V. A. Boussiotis, S. J. Shattil, and M. H. Ginsberg. 2006. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr Biol 16:17961806. Caron, E., A. J. Self, and A. Hall. 2000. The GTPase Rap1 controls functional activation of macrophage integrin alphaMbeta2 by LPS and other inflammatory mediators. Curr Biol 10:974-978. Katagiri, K., A. Maeda, M. Shimonaka, and T. Kinashi. 2003. RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat Immunol 4:741-748. Inagaki, T., S. Suzuki, T. Miyamoto, T. Takeda, K. Yamashita, A. Komatsu, K. Yamauchi, and K. Hashizume. 2003. The retinoic acid-responsive proline-rich protein is identified in promyeloleukemic HL-60 cells. J Biol Chem 278:51685-51692. Jenzora, A., B. Behrendt, J. V. Small, J. Wehland, and T. E. Stradal. 2006. PREL1 provides a link from Ras signalling to the actin cytoskeleton via Ena/VASP proteins. FEBS Lett 580:455-463. Hanks, S. K., M. B. Calalb, M. C. Harper, and S. K. Patel. 1992. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell 87. 88. 89. 90. 91. 92. 93. 94. 69 attachment to fibronectin. Proc Natl Acad Sci U S A 89:8487-8491. Schaller, M. D., C. A. Borgman, B. S. Cobb, R. R. Vines, A. B. Reynolds, and J. T. Parsons. 1992. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A 89:51925196. Lev, S., H. Moreno, R. Martinez, P. Canoll, E. Peles, J. M. Musacchio, G. D. Plowman, B. Rudy, and J. Schlessinger. 1995. Protein tyrosine kinase PYK2 involved in Ca(2+)induced regulation of ion channel and MAP kinase functions. Nature 376:737-745. Sasaki, H., K. Nagura, M. Ishino, H. Tobioka, K. Kotani, and T. Sasaki. 1995. Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem 270:21206-21219. Avraham, S., R. London, Y. Fu, S. Ota, D. Hiregowdara, J. Li, S. Jiang, L. M. Pasztor, R. A. White, J. E. Groopman, and et al. 1995. Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem 270:2774227751. Yu, H., X. Li, G. S. Marchetto, R. Dy, D. Hunter, B. Calvo, T. L. Dawson, M. Wilm, R. J. Anderegg, L. M. Graves, and H. S. Earp. 1996. Activation of a novel calcium-dependent proteintyrosine kinase. Correlation with c-Jun N-terminal kinase but not mitogenactivated protein kinase activation. J Biol Chem 271:29993-29998. Li, J., H. Avraham, R. A. Rogers, S. Raja, and S. Avraham. 1996. Characterization of RAFTK, a novel focal adhesion kinase, and its integrindependent phosphorylation and activation in megakaryocytes. Blood 88:417-428. Parsons, J. T. 2003. Focal adhesion kinase: the first ten years. J Cell Sci 116:1409-1416. Chen, H. C., P. A. Appeddu, J. T. Parsons, J. D. Hildebrand, M. D. Schaller, and J. L. Guan. 1995. 95. 96. 97. 98. 99. 100. 101. 102. 103. Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 270:16995-16999. Hildebrand, J. D., M. D. Schaller, and J. T. Parsons. 1995. Paxillin, a tyrosine phosphorylated focal adhesionassociated protein binds to the carboxyl terminal domain of focal adhesion kinase. Mol Biol Cell 6:637647. Zhai, J., H. Lin, Z. Nie, J. Wu, R. Canete-Soler, W. W. Schlaepfer, and D. D. Schlaepfer. 2003. Direct interaction of focal adhesion kinase with p190RhoGEF. J Biol Chem 278:24865-24873. Izaguirre, G., L. Aguirre, Y. P. Hu, H. Y. Lee, D. D. Schlaepfer, B. J. Aneskievich, and B. Haimovich. 2001. The cytoskeletal/non-muscle isoform of alpha-actinin is phosphorylated on its actin-binding domain by the focal adhesion kinase. J Biol Chem 276:28676-28685. Ilic, D., Y. Furuta, S. Kanazawa, N. Takeda, K. Sobue, N. Nakatsuji, S. Nomura, J. Fujimoto, M. Okada, and T. Yamamoto. 1995. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAKdeficient mice. Nature 377:539-544. Sieg, D. J., C. R. Hauck, and D. D. Schlaepfer. 1999. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci 112:2677-2691. Hsia, D. A., S. K. Mitra, C. R. Hauck, D. N. Streblow, J. A. Nelson, D. Ilic, S. Huang, E. Li, G. R. Nemerow, J. Leng, K. S. Spencer, D. A. Cheresh, and D. D. Schlaepfer. 2003. Differential regulation of cell motility and invasion by FAK. J Cell Biol 160:753-767. Gu, J., M. Tamura, R. Pankov, E. H. Danen, T. Takino, K. Matsumoto, and K. M. Yamada. 1999. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 146:389-403. Avraham, H., S. Y. Park, K. Schinkmann, and S. Avraham. 2000. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 12:123-133. 104. 105. 106. 107. 108. 109. 110. 111. 112. 70 Yan, S. R., and M. J. Novak. 1999. Beta2 integrin-dependent phosphorylation of protein-tyrosine kinase Pyk2 stimulated by tumor necrosis factor alpha and fMLP in human neutrophils adherent to fibrinogen. FEBS Lett 451:33-38. Dikic, I., and J. Schlessinger. 1998. Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J Biol Chem 273:14301-14308. Dikic, I., I. Dikic, and J. Schlessinger. 1998. Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J Biol Chem 273:14301-14308. Li, X., D. Hunter, J. Morris, J. S. Haskill, and H. S. Earp. 1998. A calcium-dependent tyrosine kinase splice variant in human monocytes. Activation by a two-stage process involving adherence and a subsequent intracellular signal. J Biol Chem 273:9361-9364. Fuortes, M., W. W. Jin, and C. Nathan. 1994. Beta 2 integrin-dependent tyrosine phosphorylation of paxillin in human neutrophils treated with tumor necrosis factor. J Cell Biol 127:14771483. Fernandez, R., and S. J. Suchard. 1998. Syk activation is required for spreading and H2O2 release in adherent human neutrophils. J Immunol 160:5154-5162. Brown, E., and N. Hogg. 1996. Where the outside meets the inside: integrins as activators and targets of signal transduction cascades. Immunol Lett 54:189-193. Dikic, I., G. Tokiwa, S. Lev, S. A. Courtneidge, and J. Schlessinger. 1996. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383:547-550. Park, S. Y., H. K. Avraham, and S. Avraham. 2004. RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Srcindependent manner. J Biol Chem 279:33315-33322. Li, X., R. C. Dy, W. G. Cance, L. M. Graves, and H. S. Earp. 1999. 113. 114. 115. 116. 117. 118. 119. 120. Interactions between two cytoskeletonassociated tyrosine kinases: calciumdependent tyrosine kinase and focal adhesion tyrosine kinase. J Biol Chem 274:8917-8924. Shi, C. S., S. Sinnarajah, H. Cho, T. Kozasa, and J. H. Kehrl. 2000. G13alpha-mediated PYK2 activation. PYK2 is a mediator of G13alpha induced serum response elementdependent transcription. J Biol Chem 275:24470-24476. Cheng, J. J., Y. J. Chao, and D. L. Wang. 2002. Cyclic strain activates redox-sensitive prolin-rich tyrosine kinase 2 (PYK2) in endothelial cells. J Biol Chem. Astier, A., S. N. Manie, H. Avraham, H. Hirai, S. F. Law, Y. Zhang, E. A. Golemis, Y. Fu, B. J. Druker, N. Haghayeghi, A. S. Freedman, and S. Avraham. 1997. The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Caslike protein, p105HEF1. J Biol Chem 272:19719-19724. Astier, A., H. Avraham, S. N. Manie, J. Groopman, T. Canty, S. Avraham, and A. S. Freedman. 1997. The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta1integrin stimulation in B cells and binds to p130cas. J Biol Chem 272:228-232. Ohba, T., M. Ishino, H. Aoto, and T. Sasaki. 1998. Interaction of two proline-rich sequences of cell adhesion kinase beta with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf. Biochem J 330 (Pt 3):1249-1254. Schlaepfer, D. D., C. R. Hauck, and D. J. Sieg. 1999. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71:435-478. Gismondi, A., L. Bisogno, F. Mainiero, G. Palmieri, M. Piccoli, L. Frati, and A. Santoni. 1997. Prolinerich tyrosine kinase-2 activation by beta 1 integrin fibronectin receptor cross-linking and association with paxillin in human natural killer cells. J Immunol 159:4729-4736. Hiregowdara, D., H. Avraham, Y. Fu, R. London, and S. Avraham. 1997. 121. 122. 123. 124. 125. 126. 127. 128. 71 Tyrosine phosphorylation of the related adhesion focal tyrosine kinase in megakaryocytes upon stem cell factor and phorbol myristate acetate stimulation and its association with paxillin. J Biol Chem 272:1080410810. Fuortes, M., M. Melchior, H. Han, G. J. Lyon, and C. Nathan. 1999. Role of the tyrosine kinase pyk2 in the integrin-dependent activation of human neutrophils by TNF. J Clin Invest 104:327-335. Litvak, V., D. Tian, Y. D. Shaul, and S. Lev. 2000. Targeting of PYK2 to focal adhesions as a cellular mechanism for convergence between integrins and G protein-coupled receptor signaling cascades. J Biol Chem 275:32736-32746. Andreev, J., J. P. Simon, D. D. Sabatini, J. Kam, G. Plowman, P. A. Randazzo, and J. Schlessinger. 1999. Identification of a new Pyk2 target protein with Arf-GAP activity. Mol Cell Biol 19:2338-2350. Lev, S., J. Hernandez, R. Martinez, A. Chen, G. Plowman, and J. Schlessinger. 1999. Identification of a novel family of targets of PYK2 related to Drosophila retinal degeneration B (rdgB) protein. Mol Cell Biol 19:2278-2288. Avraham, S., and H. Avraham. 1997. Characterization of the novel focal adhesion kinase RAFTK in hematopoietic cells. Leuk Lymphoma 27:247-256. Girault, J. A., A. Costa, P. Derkinderen, J. M. Studler, and M. Toutant. 1999. FAK and PYK2/CAKbeta in the nervous system: a link between neuronal activity, plasticity and survival? Trends Neurosci 22:257-263. Parent, C. A. 2004. Making all the right moves: chemotaxis in neutrophils and Dictyostelium. Curr Opin Cell Biol 16:4-13. Heit, B., S. Tavener, E. Raharjo, and P. Kubes. 2002. An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol 159:91-102. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. Heit, B., P. Colarusso, and P. Kubes. 2005. Fundamentally different roles for LFA-1, Mac-1 and alpha4-integrin in neutrophil chemotaxis. J Cell Sci 118:5205-5220. Niggli, V. 2003. Signaling to migration in neutrophils: importance of localized pathways. Int J Biochem Cell Biol 35:1619-1638. Six, D. A., and E. A. Dennis. 2000. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488:1-19. Balsinde, J., R. Perez, and M. A. Balboa. 2006. Calcium-independent phospholipase A2 and apoptosis. Biochim Biophys Acta 1761:13441350. Li, Q., V. Subbulakshmi, C. M. Oldfield, R. Aamir, C. M. Weyman, A. Wolfman, and M. K. Cathcart. 2007. PKCalpha regulates phosphorylation and enzymatic activity of cPLA2 in vitro and in activated human monocytes. Cell Signal 19:359-366. Lee, H. Y., M. K. Kim, K. S. Park, E. H. Shin, and Y. S. Bae. 2005. Group IB secretory phospholipase A2 stimulates leukotriene B4 production by a unique mechanism in human neutrophils. Biochem Biophys Res Commun 334:500-508. Takasaki, J., Y. Kawauchi, T. Yasunaga, and Y. Masuho. 1996. Human type II phospholipase A2induced Mac-1 expression on human neutrophils. J Leukoc Biol 60:174-180. Yedgar, S., Y. Cohen, and D. Shoseyov. 2006. Control of phospholipase A2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 1761:13731382. Klugewitz, K., K. Ley, D. Schuppan, R. Nuck, P. Gaehtgens, and B. Walzog. 1997. Activation of the beta2 integrin Mac-1 (CD11b/CD18) by an endogenous lipid mediator of human neutrophils and HL-60 cells. J Cell Sci 110 (Pt 8):985-990. Della Bianca, V., M. Grzeskowiak, and F. Rossi. 1990. Studies on molecular regulation of phagocytosis and activation of the NADPH oxidase 139. 140. 141. 142. 143. 144. 145. 146. 72 in neutrophils. IgG- and C3b-mediated ingestion and associated respiratory burst independent of phospholipid turnover and Ca2+ transients. J Immunol 144:1411-1417. Balsinde, J., M. V. Winstead, and E. A. Dennis. 2002. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 531:2-6. Glenn, H. L., and B. S. Jacobson. 2002. Arachidonic acid signaling to the cytoskeleton: The role of cyclooxygenase and cyclic AMPdependent protein kinase in actin bundling. Cell Motil Cytoskeleton 53:239-250. Moghaddami, N., M. Costabile, P. K. Grover, H. P. Jersmann, Z. H. Huang, C. S. Hii, and A. Ferrante. 2003. Unique effect of arachidonic acid on human neutrophil TNF receptor expression: up-regulation involving protein kinase C, extracellular signalregulated kinase, and phospholipase A2. J Immunol 171:2616-2624. Palmantier, R., J. D. Roberts, W. C. Glasgow, T. Eling, and K. Olden. 1996. Regulation of the adhesion of a human breast carcinoma cell line to type IV collagen and vitronectin: roles for lipoxygenase and protein kinase C. Cancer Res 56:2206-2212. Pellegrini, G., R. Malandra, A. Celi, B. C. Furie, B. Furie, and R. Lorenzet. 1998. 12-Hydroxyeicosatetraenoic acid upregulates P-selectin-induced tissue factor activity on monocytes. FEBS Lett 441:463-466. Jacobson, P. B., and D. J. Schrier. 1993. Regulation of CD11b/CD18 expression in human neutrophils by phospholipase A2. J Immunol 151:5639-5652. Shmelzer, Z., N. Haddad, E. Admon, I. Pessach, T. L. Leto, Z. Eitan-Hazan, M. Hershfinkel, and R. Levy. 2003. Unique targeting of cytosolic phospholipase A2 to plasma membranes mediated by the NADPH oxidase in phagocytes. J Cell Biol 162:683-692. Kerkhoff, C., W. Nacken, M. Benedyk, M. C. Dagher, C. Sopalla, and J. Doussiere. 2005. The arachidonic acid-binding protein 147. 148. 149. 150. 151. 152. 153. 154. 155. S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. Faseb J 19:467469. Serhan, C. N., and E. Oliw. 2001. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest 107:1481-1489. McMahon, B., S. Mitchell, H. R. Brady, and C. Godson. 2001. Lipoxins: revelations on resolution. Trends Pharmacol Sci 22:391-395. Lee, T. H., C. E. Horton, U. KyanAung, D. Haskard, A. E. Crea, and B. W. Spur. 1989. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and Nformyl-L-methionyl-L-leucyl-Lphenylalanine. Clin Sci (Lond) 77:195203. Papayianni, A., C. N. Serhan, and H. R. Brady. 1996. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 156:22642272. Fiore, S., and C. N. Serhan. 1995. Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4lipoxin A4 receptor interaction. Biochemistry 34:16678-16686. Hachicha, M., M. Pouliot, N. A. Petasis, and C. N. Serhan. 1999. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 189:1923-1930. Chiang, N., M. Arita, and C. N. Serhan. 2005. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 73:163-177. Maddox, J. F., and C. N. Serhan. 1996. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 183:137-146. 156. 157. 158. 159. 160. 161. 162. 163. 164. 73 Serhan, C. N., J. F. Maddox, N. A. Petasis, I. Akritopoulou-Zanze, A. Papayianni, H. R. Brady, S. P. Colgan, and J. L. Madara. 1995. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34:1460914615. Serhan, C. N. 2002. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 6869:433-455. Reville, K., J. K. Crean, S. Vivers, I. Dransfield, and C. Godson. 2006. Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J Immunol 176:1878-1888. Aderem, A., and D. M. Underhill. 1999. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 17:593-623. Berton, G., S. R. Yan, L. Fumagalli, and C. A. Lowell. 1996. Neutrophil activation by adhesion: mechanisms and pathophysiological implications. Int J Clin Lab Res 26:160-177. Hellberg, C., L. Molony, L. Zheng, and T. Andersson. 1996. Ca2+ signalling mechanisms of the beta 2 integrin on neutrophils: involvement of phospholipase C gamma 2 and Ins(1,4,5)P3. Biochem J 317:403-409. Bokoch, G. M., and B. A. Diebold. 2002. Current molecular models for NADPH oxidase regulation by Rac GTPase. Blood 100:2692-2696. Diebold, B. A., and G. M. Bokoch. 2005. Rho GTPases and the control of the oxidative burst in polymorphonuclear leukocytes. Curr Top Microbiol Immunol 291:91-111. Diebold, B. A., B. Fowler, J. Lu, M. C. Dinauer, and G. M. Bokoch. 2004. Antagonistic cross-talk between Rac and Cdc42 GTPases regulates generation of reactive oxygen species. J Biol Chem 279:28136-28142. Tamura, M., M. Kanno, and T. Kai. 2001. Destabilization of neutrophil NADPH oxidase by ATP and other trinucleotides and its prevention by 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. Mg(2+). Biochim Biophys Acta 1510:270-277. Tamura, M., M. Kanno, and Y. Endo. 2000. Deactivation of neutrophil NADPH oxidase by actindepolymerizing agents in a cell-free system. Biochem J 349:369-375. Berton, G. 1999. Degranulation. Lippinkott Williams & Wilkins, Philladelphia. Henson, P. M., J. E. Henson, C. Fittschen, G. Kimani, D. L. Bratton, and D. W. H. Riches. 1992. Degranulation and secretion by phagocytic cells. Raven Press Ltd., New York. Allen, L. A., and A. Aderem. 1996. Mechanisms of phagocytosis. Curr Opin Immunol 8:36-40. Collins, S. J. 1987. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70:1233-1244. Tithof, P. K., M. Peters-Golden, and P. E. Ganey. 1998. Distinct phospholipases A2 regulate the release of arachidonic acid for eicosanoid production and superoxide anion generation in neutrophils. J Immunol 160:953-960. Diamond, M. S., and T. A. Springer. 1993. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol 120:545-556. Dransfield, I., and N. Hogg. 1989. Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits. Embo J 8:3759-3765. Kotovuori, A., T. Pessa-Morikawa, P. Kotovuori, P. Nortamo, and C. G. Gahmberg. 1999. ICAM-2 and a peptide from its binding domain are efficient activators of leukocyte adhesion and integrin affinity. J Immunol 162:6613-6620. Zhou, X., J. Li, and D. F. Kucik. 2001. The Microtubule Cytoskeleton Participates in Control of beta 2 Integrin Avidity. J Biol Chem 276:44762-44769. Schenborn, E. T. 2000. Transfection technologies. Methods Mol Biol 130:91-102. 177. 178. 179. 180. 181. 182. 183. 184. 185. 74 Colosimo, A., K. K. Goncz, A. R. Holmes, K. Kunzelmann, G. Novelli, R. W. Malone, M. J. Bennett, and D. C. Gruenert. 2000. Transfer and expression of foreign genes in mammalian cells. Biotechniques 29:314-318, 320-312, 324 passim. Brigati, C., M. Giacca, D. M. Noonan, and A. Albini. 2003. HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol Lett 220:57-65. Frankel, A. D., and C. O. Pabo. 1988. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193. Green, M., and P. M. Loewenstein. 1988. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 55:1179-1188. Nagahara, H., A. M. Vocero-Akbani, E. L. Snyder, A. Ho, D. G. Latham, N. A. Lissy, M. Becker-Hapak, S. A. Ezhevsky, and S. F. Dowdy. 1998. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4:1449-1452. Becker-Hapak, M., S. S. McAllister, and S. F. Dowdy. 2001. TAT-mediated protein transduction into mammalian cells. Methods 24:247-256. Klekotka, P. A., S. A. Santoro, A. Ho, S. F. Dowdy, and M. M. Zutter. 2001. Mammary epithelial cell-cycle progression via the alpha(2)beta(1) integrin: unique and synergistic roles of the alpha(2) cytoplasmic domain. Am J Pathol 159:983-992. Cougoule, C., A. Wiedemann, J. Lim, and E. Caron. 2004. Phagocytosis, an alternative model system for the study of cell adhesion. Semin Cell Dev Biol 15:679-689. Zhou, X., J. Li, and D. F. Kucik. 2001. The microtubule cytoskeleton participates in control of beta2 integrin avidity. J Biol Chem 276:4476244769. Bazzoni, G., and M. E. Hemler. 1998. Are changes in integrin affinity and conformation overemphasized? Trends Biochem Sci 23:30-34. 186. 187. 188. 189. 190. Luster, A. D., R. Alon, and U. H. von Andrian. 2005. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6:1182-1190. Greenwood, J., L. Steinman, and S. S. Zamvil. 2006. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358-370. Chun, J. S., and B. S. Jacobson. 1992. Spreading of HeLa cells on a collagen substratum requires a second messenger formed by the lipoxygenase metabolism of arachidonic acid released by collagen receptor clustering. Mol Biol Cell 3:481-492. Aderem, A. A., S. D. Wright, S. C. Silverstein, and Z. A. Cohn. 1985. Ligated complement receptors do not activate the arachidonic acid cascade in resident peritoneal macrophages. J Exp Med 161:617-622. 191. 192. 75 Corey, S. J., and P. M. Rosoff. 1991. Unsaturated fatty acids and lipoxygenase products regulate phagocytic NADPH oxidase activity by a nondetergent mechanism. J Lab Clin Med 118:343-351. Huang, Z. H., C. S. Hii, D. A. Rathjen, A. Poulos, A. W. Murray, and A. Ferrante. 1997. N-6 and n-3 polyunsaturated fatty acids stimulate translocation of protein kinase Calpha, -betaI, -betaII and -epsilon and enhance agonist-induced NADPH oxidase in macrophages. Biochem J 325 (Pt 2):553-557. Han, H., M. Fuortes, and C. Nathan. 2003. Critical role of the carboxyl terminus of proline-rich tyrosine kinase (Pyk2) in the activation of human neutrophils by tumor necrosis factor: separation of signals for the respiratory burst and degranulation. J Exp Med 197:63-75.